[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1989
1. Weiss S, Siebzehnrübl FA, Kreutzer J, Blümcke I, Buslei R: Evidence for a progenitor cell population in the human pituitary. Clin Neuropathol; 2009 Jul-Aug;28(4):309-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a progenitor cell population in the human pituitary.
  • This will also apply to the pituitary gland, i.e., following tumor induced endocrine deficiency.
  • In tissue sections of the anterior lobe nestin immunoreactive cells co-expressing smooth muscle actin (SMA) were identified in the perivascular space, indicating a pericytic differentiation.
  • Pituitary cell cultures maintained a stable cell cycle length with a doubling time of 10 days for over eight months.
  • The presence of sphere-forming, nestin-immunoreactive cells and their ability to generate differentiated cell lineages indicates the existence of a progenitor cell population persisting in the adult human pituitary.
  • Further studies are needed to characterize this cell population in more detail and to clarify their potential to initiate neoplastic transformation for example in the cellular pathogenesis of pituitary adenoma.
  • [MeSH-major] Pituitary Gland / cytology. Stem Cells / cytology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642511.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


2. Ronson BB, Schulte RW, Han KP, Loredo LN, Slater JM, Slater JD: Fractionated proton beam irradiation of pituitary adenomas. Int J Radiat Oncol Biol Phys; 2006 Feb 1;64(2):425-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated proton beam irradiation of pituitary adenomas.
  • PURPOSE: Various radiation techniques and modalities have been used to treat pituitary adenomas.
  • METHODS AND MATERIALS: Forty-seven patients with pituitary adenomas treated with protons, who had at least 6 months of follow-up, were included in this analysis.
  • Seventeen patients with functional adenomas had normalized or decreased hormone levels; progression occurred in 3 patients.
  • Complications included temporal lobe necrosis in 1 patient, new significant visual deficits in 3 patients, and incident hypopituitarism in 11 patients.
  • CONCLUSION: Fractionated conformal proton-beam irradiation achieved effective radiologic, endocrinological, and symptomatic control of pituitary adenomas.
  • [MeSH-major] Adenoma / radiotherapy. Pituitary Neoplasms / radiotherapy. Protons / therapeutic use

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16257131.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 9002-60-2 / Adrenocorticotropic Hormone; 9002-71-5 / Thyrotropin
  •  go-up   go-down


3. Garzaro M, Pecorari G, Landolfo V, Campisi P, Reali A, Giordano C: Nasopharyngeal polymorphous low-grade adenocarcinoma in a patient with nonfunctioning pituitary macroadenoma. B-ENT; 2010;6(1):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal polymorphous low-grade adenocarcinoma in a patient with nonfunctioning pituitary macroadenoma.
  • The incidence of clinically recognisable pituitary adenoma is 15 cases/million/year.
  • The prevalence of non-functioning pituitary adenoma (NFPA) is estimated to be 70-90 cases/million.
  • Both types of adenoma represent 20-45% of pituitary tumours.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Nasopharyngeal Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Pituitary Neoplasms / surgery


Advertisement
4. Ren ZY, Yang Y, Su CB, Wang RZ, Tao W, Ma WB, Li YN: [Relationship between invasive pituitary adenomas and cavernus sinus and cariod artery and surgical outcomes]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb;27(1):13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between invasive pituitary adenomas and cavernus sinus and cariod artery and surgical outcomes].
  • OBJECTIVE: To analyze the relationship between invasive pituitary adenomas and cavernus sinus and cariod artery and to predict their surgical outcomes.
  • METHODS: Totally 270 patients with pituitary tumors were investigated in this retrospective study, including 113 men and 157 women, with a mean age of 40.8 years.
  • Pituitary microadenomas were diagnosed in 56 cases, macroadenomas in 118 cases, and hugeadenomas in 96 cases.
  • Adrenocorticotropic hormone-releasing adenomas (Cushing's diseases) were diagnosed in 40 cases, growth hormone-releasing adenomas in 58 cases, prolactinomas in 57 cases, and non-functional pituitary adenomas in 115 cases.
  • RESULTS: The percentage of invasive pituitary adenomas was about 3.6% in microadenomas, 20.4% in macroadenomas, and 61.4% in hugeadenomas.
  • Rate of total removal was 94.1% in non-invasive pituitary adenomas, and was 58.8% in invasive pituitary adenomas.
  • CONCLUSIONS: It is important to analyze the grade of invasive pituitary adenomas to improve the removal of pituitary adenomas, avoid injuring cariod artery, and increase the rate of total removal.
  • [MeSH-major] Adenoma / surgery. Carotid Arteries / pathology. Cavernous Sinus / pathology. Pituitary ACTH Hypersecretion / surgery. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782485.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


5. Psaras T, Honegger J, Buslei R, Saeger W, Klein D, Capper D, Meyermann R, Mittelbronn M: Atypical type II silent corticotrophic adenoma developing into Cushing's disease upon second recurrence. Exp Clin Endocrinol Diabetes; 2007 Oct;115(9):610-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical type II silent corticotrophic adenoma developing into Cushing's disease upon second recurrence.
  • Herein, we report the case of a 73-year old male patient who presented with two recurrences of a pituitary adenoma within a period of 15 years.
  • The first tumor resection 15 years ago revealed a non-functioning pituitary macroadenoma.
  • A retrospective analysis of all histological and immunohistochemical slides rendered an adenoma exhibiting chromophobia, ACTH-positivity and features of atypia such as elevated p53 and Ki67 expression as well as nuclear polymorphism.
  • According to the revised WHO classification it was classified as atypical type II silent corticotroph adenoma at the time of the first and second surgery.
  • The specimen removed during the recent surgery displayed the same histological features and was classified as corticotroph adenoma.
  • The combination of an atypical type II adenoma and the switch in the hormone status to an endocrinologically active adenoma makes this case exceedingly rare.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / pathology. Neoplasm Recurrence, Local / pathology. Pituitary ACTH Hypersecretion / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943697.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


6. Tropinskaia OF, Shishkina LV, Shkarubo AN, Astaf'eva LI, Shimanskiĭ VN: [Rare observation of giant pituitary adenoma spreading into posterior cranial fossa]. Zh Vopr Neirokhir Im N N Burdenko; 2009 Oct-Dec;(4):54-5; discussion 56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare observation of giant pituitary adenoma spreading into posterior cranial fossa].
  • A case observation of unusual course of pituitary adenoma is presented.
  • In 47-year old male patient with endo-supra-laterosellar pituitary adenoma and active acromegaly 2 different tumors were discovered intraoperatively during surgery for recurrence of the primary tumor.
  • The first tumor was pituitary adenoma with nuclear polymorphism and the second was meningotheliomatous meningioma with solitary mitoses.
  • After removal of posterior fossa lesion, pituitary adenoma was verified.
  • [MeSH-major] Adenoma / pathology. Cerebellar Neoplasms / pathology. Neoplasms, Second Primary / pathology. Pituitary Neoplasms / pathology. Skull Base Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20143613.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


7. Starke RM, Williams BJ, Vance ML, Sheehan JP: Radiation therapy and stereotactic radiosurgery for the treatment of Cushing's disease: an evidence-based review. Curr Opin Endocrinol Diabetes Obes; 2010 Aug;17(4):356-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: The indications, efficacy, and safety of radiation therapy and stereotactic radiosurgery for Cushing's disease are evaluated.We queried PubMed using the terms, 'Cushing's disease', 'radiotherapy', and 'radiosurgery', then evaluated each study for the number of patients, method of radiation delivery, type of radiation therapy or radiosurgical device used, treatment parameters (e.g. maximal dose, tumor margin dose), length of follow-up, tumor-control rate, complications, rate of hormone normalization, newly onset loss of pituitary function, and method used to assess endocrine remission.
  • SUMMARY: Radiosurgery and, in the modern era, less commonly, radiation therapy, offer both well tolerated and reasonably effective treatment for recurrent or residual Cushing's adenomas.
  • [MeSH-major] Pituitary ACTH Hypersecretion / radiotherapy. Pituitary ACTH Hypersecretion / surgery. Radiosurgery / methods. Radiotherapy / methods
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / radiotherapy. ACTH-Secreting Pituitary Adenoma / surgery. Adenoma / radiotherapy. Adenoma / surgery. Evidence-Based Practice / methods. Evidence-Based Practice / trends. Humans. Preoperative Care / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20531182.001).
  • [ISSN] 1752-2978
  • [Journal-full-title] Current opinion in endocrinology, diabetes, and obesity
  • [ISO-abbreviation] Curr Opin Endocrinol Diabetes Obes
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 95
  •  go-up   go-down


8. Meas T, Sobngwi E, Vexiau P, Boudou P: An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant. Ann Endocrinol (Paris); 2006 Jun;67(3):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant.
  • We describe the first case of a 36 year-old male patient with a somatotropin and thyreotropin secreting pituitary adenoma, co-treated by a long-acting releasing somatostatin analog (Octreotide) and a GH receptor antagonist (Pegvisomant).
  • [MeSH-major] Adenoma / drug therapy. Adenoma / secretion. Antineoplastic Agents / therapeutic use. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / secretion. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / secretion. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840917.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


9. Toledo RA, Lourenço DM Jr, Toledo SP: Familial isolated pituitary adenoma: evidence for genetic heterogeneity. Front Horm Res; 2010;38:77-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial isolated pituitary adenoma: evidence for genetic heterogeneity.
  • The identification of mutations in the Aryl hydrocarbon receptor interacting protein (AIP) gene in a subset of familial isolated pituitary adenoma (FIPA) cases has recently expanded our understanding of the pathophysiology of inherited pituitary adenoma disorders.
  • Several studies and reviews have assessed the genetic and clinical features of AIP-mutated FIPA patients, which range from a complete lack of symptoms in adult/elderly individuals to large, aggressive early-onset pituitary tumors.
  • [MeSH-major] Adenoma / genetics. Genetic Heterogeneity. Pituitary Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for familial isolated pituitary adenoma .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20616498.001).
  • [ISSN] 0301-3073
  • [Journal-full-title] Frontiers of hormone research
  • [ISO-abbreviation] Front Horm Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / aryl hydrocarbon receptor-interacting protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Number-of-references] 41
  •  go-up   go-down


10. Mor E, Rodi IA, Bayrak A, Paulson RJ, Sokol RZ: Diagnosis of pituitary gonadotroph adenomas in reproductive-aged women. Fertil Steril; 2005 Sep;84(3):757
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of pituitary gonadotroph adenomas in reproductive-aged women.
  • OBJECTIVE: To describe the clinical symptoms associated with the diagnosis of pituitary gonadotroph adenoma in premenopausal women.
  • PATIENT(S): Three patients: a 31-year-old woman with primary infertility, recurrent adnexal masses, and highly elevated estradiol level; a 30-year-old woman with recurrent multicystic ovaries following multiple cystectomies and transvaginal cyst aspirations, and elevated estradiol level; a 43-year-old woman with bilateral complex cystic adnexal masses and an elevated estradiol level, who underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a suspected granulosa cell tumor.
  • INTERVENTION(S): Transsphenoidal resection of a pituitary mass.
  • MAIN OUTCOME MEASURE(S): Serum estradiol, FSH, and LH levels; transvaginal ultrasonography of the ovaries; histologic examination of pituitary tumors.
  • RESULT(S): Transsphenoidal resection of pituitary adenomas resulted in normalization of serum estradiol and FSH levels and resolution of adnexal masses in two of the women.
  • CONCLUSION(S): Pituitary gonadotroph adenoma must be considered in the differential diagnosis in reproductive-aged women presenting with the clinical symptom triad of new onset oligomenorrhea, bilateral cystic adnexal masses, and elevated estradiol and FSH levels with suppressed levels of LH; timely diagnosis may prevent unnecessary and potentially damaging surgical procedures.
  • [MeSH-major] Adenoma / diagnosis. Pituitary Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169418.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Fontana E, Gaillard R: [Epidemiology of pituitary adenoma: results of the first Swiss study]. Rev Med Suisse; 2009 Oct 28;5(223):2172-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiology of pituitary adenoma: results of the first Swiss study].
  • [Transliterated title] Epidémiologie des adénomes hypophysaires: étude dans une agglomération urbaine de Suisse.
  • Epidemiological data concerning pituitary adenomas are very scarce and in some cases reports are even conflicting.
  • The aim of this study was, therefore, to evaluate in the urban area of Fribourg, the prevalence of relevant clinical pituitary adenoma.
  • General practitioners, endocrinologists and gynaecologists were questioned concerning any patient within this agglomeration presenting with a pituitary micro- or macro-adenoma.
  • Among the 44 adenomas, we observed 13 non secreting macro-adenomas, 16 micro- and 9 macro-prolactinomas, 4 cases of acromegaly and 2 ACTH-dependant Cushing diseases.
  • In the studied area we found a prevalence of 80.5 pituitary adenomas per 100,000, or 1 case per 1241 corroborating a greater prevalence of pituitary adenomas than previously believed.
  • [MeSH-major] Adenoma / epidemiology. Pituitary Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968031.001).
  • [ISSN] 1660-9379
  • [Journal-full-title] Revue médicale suisse
  • [ISO-abbreviation] Rev Med Suisse
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Ben Salem Hachmi L, Kammoun I, Bouzid C, Smida H, Nagi S, Turki Z, Ben Slama C: [Management of acromegaly in pregnant woman]. Ann Endocrinol (Paris); 2010 Feb;71(1):60-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prise en charge de l'acromégalie évolutive au cours de la grossesse.
  • On the other hand, pregnancy may cause an enlargement of the adenoma or an increase of growth hormone (GH) secretion.
  • We report the case of a 26-year-old woman with a GH-secreting pituitary macroadenoma who was operated by transphenoidal approach.
  • Lanreotide was stopped when the diagnosis of pregnancy was established.
  • The pituitary adenoma was not significantly enlarged during pregnancy.
  • [MeSH-major] Acromegaly / surgery. Adenoma / surgery. Growth Hormone-Secreting Pituitary Adenoma / surgery. Pregnancy Complications / surgery

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19926070.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


13. Inguenault C, Capon-Degardin N, Martinot-Duquennoy V, Pellerin P: [Galactorrhea after mammary plastic surgery]. Ann Chir Plast Esthet; 2005 Apr;50(2):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Postsurgical galactorrhoea often follows a benign course culminating in spontaneous resolution.
  • However, it may reveal the presence of o prolactin secreting adenoma, as was the case with one of our patients.
  • If serum prolactin levels exceed 150 ng/ml further investigation by way of an MRI of the sella turcica is advisable to rule out pituitary adenoma.

  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820605.001).
  • [ISSN] 0294-1260
  • [Journal-full-title] Annales de chirurgie plastique et esthétique
  • [ISO-abbreviation] Ann Chir Plast Esthet
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


14. Saeki N, Murai H, Hasegawa Y, Horiguchi K, Hanazawa T: [Endoscopic endonasal transsphenoidal surgery for pituitary adenomas]. No Shinkei Geka; 2007 Oct;35(10):971-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic endonasal transsphenoidal surgery for pituitary adenomas].
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Hypophysectomy / methods. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969333.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


15. Bellut D, Hlavica M, Schmid C, Bernays RL: Intraoperative magnetic resonance imaging-assisted transsphenoidal pituitary surgery in patients with acromegaly. Neurosurg Focus; 2010 Oct;29(4):E9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative magnetic resonance imaging-assisted transsphenoidal pituitary surgery in patients with acromegaly.
  • OBJECT: Acromegaly is a rare disease, usually caused by a growth hormone (GH)-producing pituitary adenoma.
  • METHODS: A series of 39 consecutive transsphenoidal iMR imaging-guided (using the PoleStar N20 device) surgical procedures performed between September 2005 and August 2009 for GH-producing pituitary adenomas was retrospectively analyzed.
  • RESULTS: Thirty-seven patients with acromegaly underwent 39 transsphenoidal surgeries for pituitary adenomas.
  • CONCLUSIONS: In this largest study to date of GH-producing pituitary adenomas in which iMR imaging-guided transsphenoidal surgery was analyzed, the results suggest that this method is a highly effective and safe treatment modality, even compared with previously published surgical series in which high-field iMR imaging was used.
  • [MeSH-major] Acromegaly / surgery. Growth Hormone-Secreting Pituitary Adenoma / surgery. Intraoperative Care / methods. Magnetic Resonance Imaging / methods. Neurosurgical Procedures / methods
  • [MeSH-minor] Adenoma / surgery. Adult. Female. Follow-Up Studies. Human Growth Hormone / secretion. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm, Residual / diagnosis. Pituitary Neoplasms / surgery. Remission Induction. Sphenoid Sinus. Treatment Outcome

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887134.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


16. Liu ZX, Yuan XR, Fang JS, Huang J, Li YB, Luo C, Yang ZQ, Liu YS: [Mononostril-septum-transsphenoidal approach for pituitary adenoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Apr;31(2):281-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mononostril-septum-transsphenoidal approach for pituitary adenoma].
  • OBJECTIVE: To summarize the mononostril-septum-transsphenoidal approach for pituitary adenoma.
  • METHODS: The clinical features, operative techniques, and outcome of 36 patients with pituitary adenoma were analyzed retrospectively.
  • [MeSH-major] Adenoma / surgery. Nasal Septum / surgery. Pituitary Neoplasms / surgery. Sphenoid Sinus / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16706134.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Cavallo LM, Prevedello D, Esposito F, Laws ER Jr, Dusick JR, Messina A, Jane JA Jr, Kelly DF, Cappabianca P: The role of the endoscope in the transsphenoidal management of cystic lesions of the sellar region. Neurosurg Rev; 2008 Jan;31(1):55-64; discussion 64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic mass lesions within the sella turcica are common, and they include cystic pituitary adenomas, craniopharyngiomas, Rathke's cleft cysts, arachnoid cysts, and other entities.
  • The series consisted of 26 pituitary macroadenomas, 20 Rathke's cleft cysts, 18 craniopharyngiomas, 10 arachnoid cysts, one craniopharyngioma associated with an adrenocorticotropic hormone-secreting adenoma, and one chordoid glioma.
  • Endoscopic exploration of the sellar cavity during transsphenoidal surgery offers both general and specific advantages in the treatment of a variety of different cystic sellar lesions.
  • [MeSH-minor] Adenoma / surgery. Adult. Aged. Arachnoid Cysts / surgery. Central Nervous System Cysts / surgery. Craniopharyngioma / surgery. Female. Humans. Male. Middle Aged. Neurosurgical Procedures / instrumentation. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Sphenoid Sinus

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1991 Jun;35(6):446-54 [2053058.001]
  • [Cites] Front Horm Res. 2006;34:105-26 [16474218.001]
  • [Cites] Neurosurgery. 2005;56(1):124-8; discussion 129 [15617594.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):7-16; discussion 16-7 [9442498.001]
  • [Cites] Diagn Cytopathol. 1999 Mar;20(3):137-47 [10086237.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(2):165-9 [10189498.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):3972-82 [10566636.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):933-40; discussion 940-1 [15458602.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):696-700 [16041618.001]
  • [Cites] Surg Neurol. 1981 Apr;15(4):274-82 [7245014.001]
  • [Cites] Minim Invasive Neurosurg. 2002 Mar;45(1):47-51 [11932826.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):8-13 [6689730.001]
  • [Cites] Skull Base. 2003 Feb;13(1):55-58 [15912160.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(4):389-97; discussion 397-8 [10352749.001]
  • [Cites] Childs Nerv Syst. 2004 Nov;20(11-12):863-7 [15185112.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1970 Jul;33(1):48-53 [5427027.001]
  • [Cites] J Neurosurg. 1980 May;52(5):661-6 [7373393.001]
  • [Cites] J Endocrinol Invest. 2004 Nov;27(10):943-8 [15762042.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:57-63 [7841079.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):3-11 [12134929.001]
  • [Cites] Laryngoscope. 1996 Jul;106(7):914-8 [8667994.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):350-8 [12593622.001]
  • [Cites] Neurosurgery. 2001 Jul;49(1):94-100; discussion 100-1 [11440465.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 May;15(5):821-7 [8059648.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):451-8 [894347.001]
  • (PMID = 17922153.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


18. Zhang QH, Liu HS, Yang DZ, Cheng JY: [Image-guided endoscopic transsphenoidal removal of pituitary adenoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Jan;40(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Image-guided endoscopic transsphenoidal removal of pituitary adenoma].
  • OBJECTIVE: To assess the role of neuronavigation in assisting endoscopic transsphenoidal surgery for pituitary adenomas.
  • METHODS: Ten endoscopic endonasal transsphenoidal reoperations for pituitary adenomas were selected.
  • Five of 10 patients had gigantic adenoma, 3 microadenoma, 2 large adenoma.
  • Measurements of intraoperative accuracy in the axial, coronal, and.sagittal planes indicated a mean verified system error of 1.5 mm. for pituitary adenomas.
  • [MeSH-major] Hypophysectomy / methods. Pituitary Neoplasms / surgery. Surgery, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906518.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


19. Joshi SM, Chopra IS, Powell M: Hydrocephalus caused by giant pituitary tumors: case series and guidelines for management. Br J Neurosurg; 2009 Feb;23(1):30-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydrocephalus caused by giant pituitary tumors: case series and guidelines for management.
  • Giant pituitary adenomas causing hydrocephalus are rare (Scarone P, Losa M, Mortini P, Giovanelli M.
  • [MeSH-major] Adenoma / surgery. Hydrocephalus / surgery. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery

  • Genetic Alliance. consumer health - Hydrocephalus.
  • MedlinePlus Health Information. consumer health - Hydrocephalus.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19234906.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Tamagno G, Daly AF, Deprez M, Vroonen L, Andris C, Martin D, Beckers A: Absence of hypogonadism in a male patient with a giant prolactinoma: a clinical paradox. Ann Endocrinol (Paris); 2008 Feb;69(1):47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy revealed a pituitary adenoma and subsequent hormone profiles demonstrated grossly elevated serum prolactin (131,412ng/ml), LH at the upper limit of normal and normal testosterone.
  • [MeSH-major] Hypogonadism / diagnosis. Pituitary Neoplasms / diagnosis. Prolactin / blood. Prolactinoma / diagnosis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082643.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


21. Katznelson L: Drug insight: Primary medical therapy of acromegaly. Nat Clin Pract Endocrinol Metab; 2006 Feb;2(2):109-17; quiz following 117
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acromegaly is an insidious disease that, in most cases, is a result of a pituitary adenoma that hypersecretes growth hormone (GH).
  • A role of primary medical therapy for patients de novo has been proposed, particularly with regard to somatostatin analogues.

  • Genetic Alliance. consumer health - Acromegaly.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16932265.001).
  • [ISSN] 1745-8366
  • [Journal-full-title] Nature clinical practice. Endocrinology & metabolism
  • [ISO-abbreviation] Nat Clin Pract Endocrinol Metab
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Receptors, Somatotropin; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin
  • [Number-of-references] 61
  •  go-up   go-down


22. Jensen RL, Jensen PR, Shrieve AF, Hazard L, Shrieve DC: Overall and progression-free survival and visual and endocrine outcomes for patients with parasellar lesions treated with intensity-modulated stereotactic radiosurgery. J Neurooncol; 2010 Jun;98(2):221-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients with cavernous sinus meningiomas and eight with recurrent pituitary adenomas were treated.
  • Three of the pituitary tumors were hormonally active (two with Cushing disease, one with acromegaly).
  • [MeSH-major] Disease-Free Survival. Endocrine System Diseases / etiology. Meningeal Neoplasms / surgery. Pituitary Neoplasms / surgery. Radiosurgery / adverse effects. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Clin N Am. 2000 Oct;11(4):575-86 [11082168.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2 Suppl):A19-25 [19165069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1337-45 [10889388.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):580-92 [12957272.001]
  • [Cites] Prog Neurol Surg. 2009;22:77-95 [18948721.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):607-14 [1907958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Strahlenther Onkol. 2005 May;181(5):336-44 [15900431.001]
  • [Cites] J Neurooncol. 2009 May;92(3):345-56 [19357961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1481-91 [11286857.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):43-50 [9420071.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1313-9 [11728692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1018-26 [19217219.001]
  • [Cites] Radiology. 1976 Jul;120(1):167-71 [935443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):99-109 [12504041.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):437-44 [9308948.001]
  • [Cites] Stereotact Funct Neurosurg. 2008;86(5):292-6 [18758206.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Med Dosim. 2003 Summer;28(2):85-90 [12804705.001]
  • [Cites] Important Adv Oncol. 1995;:141-56 [7672802.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1265-70 [12128128.001]
  • [Cites] Neurosurg Clin N Am. 2006 Apr;17(2):67-78, v [16793500.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2009 Jun;21(5):408-16 [19268555.001]
  • [Cites] J Med Assoc Thai. 2009 Mar;92(3):382-9 [19301733.001]
  • [Cites] Rev Endocr Metab Disord. 2009 Jun;10(2):135-44 [18787957.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):446-53; discussion 453-4 [9526976.001]
  • [Cites] Neurosurgery. 2008 May;62(5 Suppl):A2-9; discussion A9-10 [18580777.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):987-91 [12095567.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):215-21 [8407394.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1177-81 [12654424.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63 [7960976.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:219-22 [11143252.001]
  • [Cites] Otolaryngol Clin North Am. 2009 Aug;42(4):601-21 [19751867.001]
  • [Cites] Med Dosim. 2001 Summer;26(2):143-50 [11444516.001]
  • (PMID = 20461446.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, Wray J, Bishop-Bailey D, Berney DM, Wass JA, Popovic V, Ribeiro-Oliveira A Jr, Gadelha MR, Monson JP, Akker SA, Davis JR, Clayton RN, Yoshimoto K, Iwata T, Matsuno A, Eguchi K, Musat M, Flanagan D, Peters G, Bolger GB, Chapple JP, Frohman LA, Grossman AB, Korbonits M: The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab; 2008 Jun;93(6):2390-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.
  • CONTEXT: Mutations have been identified in the aryl hydrocarbon receptor-interacting protein (AIP) gene in familial isolated pituitary adenomas (FIPA).
  • OBJECTIVE: AIP sequence changes and expression were studied in FIPA and sporadic adenomas.
  • Cellular and ultrastructural AIP localization was determined in pituitary cells.
  • PATIENTS: Twenty-six FIPA kindreds and 85 sporadic pituitary adenoma patients were included in the study.
  • Overexpression of wild-type AIP in TIG3 and HEK293 human fibroblast and GH3 pituitary cell lines dramatically reduced cell proliferation, whereas mutant AIP lost this ability.
  • In normal pituitary, AIP colocalizes exclusively with GH and prolactin, and it is found in association with the secretory vesicle, as shown by double-immunofluorescence and electron microscopy staining.
  • In sporadic pituitary adenomas, however, AIP is expressed in all tumor types.
  • In addition, whereas AIP is expressed in the secretory vesicle in GH-secreting tumors, similar to normal GH-secreting cells, in lactotroph, corticotroph, and nonfunctioning adenomas, it is localized to the cytoplasm and not in the secretory vesicles.
  • The abnormal expression and subcellular localization of AIP in sporadic pituitary adenomas indicate deranged regulation of this protein during tumorigenesis.
  • [MeSH-major] Adenoma / genetics. Pituitary Neoplasms / genetics. Proteins / physiology


24. Al Brahim NY, Rambaldini G, Ezzat S, Asa SL: Complex endocrinopathies in MEN-1: diagnostic dilemmas in endocrine oncology. Endocr Pathol; 2007;18(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex endocrinopathies in MEN-1: diagnostic dilemmas in endocrine oncology.
  • Endocrine oncology is a complex area that must determine the site of a neoplastic process and the hormonal dysregulation that ensues.
  • Patients with endocrine tumors often have delayed diagnosis because of the nonspecific and often subtle signs and symptoms.
  • In patients with multiple endocrine neoplasia syndromes, diagnosis and clinicopathologic correlations can be even more challenging.
  • We report a patient with multiple endocrine neoplasia type 1 (MEN-1) and a highly complex clinical story associated with multiple atypical lesions including two pituitary adenomas, a gonadotroph macroadenoma and a corticotroph microadenoma with Crooke's hyaline change and ectopic production of corticotropin-releasing hormone (CRH) from a thymic endocrine carcinoma.
  • This case illustrates a number of clinically relevant challenges, including the diagnosis of pituitary adenomas in MEN-1, the difficulty in diagnosing Cushing's disease, and the large differential of pituitary pathologies in this disorder, double pituitary adenomas and other decoy lesions in Cushing's disease, the pathophysiology of Crooke's hyaline change in the pituitary, and the various causes of Cushing's syndrome associated with MEN-1.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 1 / pathology. Pituitary ACTH Hypersecretion / pathology. Pituitary Neoplasms / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Humans. Hyalin / metabolism. Male. Middle Aged. Pituitary Gland / metabolism. Pituitary Gland / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1991 Sep 26;325(13):897-905 [1652686.001]
  • [Cites] N Engl J Med. 1986 May 15;314(20):1287-93 [2871488.001]
  • [Cites] Endocr Pathol. 2005 Fall;16(3):187-94 [16299401.001]
  • [Cites] Endocr J. 1995 Jun;42(3):331-40 [7670561.001]
  • [Cites] Acta Neurochir (Wien). 1981;58(3-4):235-43 [6172012.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):457-65 [11836268.001]
  • [Cites] Ann Intern Med. 1986 Dec;105(6):862-7 [3022629.001]
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] Ultrastruct Pathol. 1983 Sep-Oct;5(2-3):249-55 [6322399.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):570-4 [15522929.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1619-23 [9589666.001]
  • [Cites] Endocr Pathol. 2005 Fall;16(3):201-10 [16299403.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Aug;89(8):3752-63 [15292301.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2291-5 [9661597.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1330-6 [14508394.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4963-9 [15886242.001]
  • [Cites] Semin Diagn Pathol. 1987 Aug;4(3):205-11 [2890193.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Nov;36(11):818-21 [9420436.001]
  • [Cites] Acta Endocrinol (Copenh). 1987 Jul;115(3):331-7 [2887080.001]
  • [Cites] Surg Today. 2001;31(5):428-32 [11381507.001]
  • (PMID = 17652799.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Arita K, Tominaga A, Sugiyama K, Eguchi K, Iida K, Sumida M, Migita K, Kurisu K: Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J Neurosurg; 2006 Jun;104(6):884-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination.
  • OBJECT: The increase in the incidental detection of asymptomatic pituitary adenomas, known as "pituitary incidentalomas," led the authors to conduct a survey of the natural course of these lesions.
  • METHODS: Forty-two patients with clinically nonfunctioning pituitary adenomas who had manifested no neurological or endocrinological disorders were monitored with magnetic resonance imaging studies.
  • This increase was first detected between 8.4 and 58.8 months (mean 31.8 +/- 17.6 months) after diagnosis.
  • Symptoms were noted in 10 patients during follow up; in four, extensive tumor necrosis accompanied hemorrhage, leading to severe headache, acute ophthalmological symptoms, and panhypopituitarism, which was indicative of pituitary apoplexy.
  • During the 5-year follow up, pituitary apoplexy developed in 9.5%.
  • [MeSH-major] Adenoma / pathology. Pituitary Apoplexy / epidemiology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776331.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ergungor F, Daglioglu E, Akdemir G, Okay O, Dalgic A, Hatipoglu G: Delayed chiasmal herniation after transsphenoidal removal of a pituitary adenoma - case report. Neurol Neurochir Pol; 2008 Jan-Feb;42(1):60-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed chiasmal herniation after transsphenoidal removal of a pituitary adenoma - case report.
  • We report a 41-year-old woman who experienced visual deterioration after successful removal of a pituitary adenoma.
  • Possible mechanisms of this visual deterioration and contribution of chiasmal herniation into the sella as well as defect in the diaphragma sellae are discussed with emphasis on the regulation of medical treatment for pituitary adenomas.
  • We conclude that medical therapy after pituitary surgery should be carefully managed together with periodic visual examinations.
  • [MeSH-major] Encephalocele / etiology. Hypophysectomy / adverse effects. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365965.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


27. Widdel L, Kleinschmidt-DeMasters BK, Kindt G: Tumor-to-tumor metastasis from hematopoietic neoplasms to meningiomas: report of two patients with significant cerebral edema. World Neurosurg; 2010 Jul;74(1):165-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Often there are limited clinical consequences and the condition is an incidental finding identified only on microscopic examination of a resected specimen.
  • OBJECTIVE: To report two examples of benign meningiomas in which metastatic tumor deposits from the patient's hematopoietic neoplasm to the meningioma caused significant peritumoral edema, necessitating semiemergent surgical resection.
  • RESULTS: One patient had multiple myeloma associated with extensive necrosis within his otherwise benign convexity meningioma; first diagnosis of his IgG, kappa-restricted plasma cell dyscrasia was made from this tumor-to-tumor meningioma specimen.
  • The second patient carried a diagnosis of marginal zone lymphoma but then presented 5 years later with symptoms referable to a large dural-based mass with significant surrounding edema, prompting surgical removal.
  • Dural marginal zone lymphoma was identified within epidural, intradural, and subdural spaces, in the same location as an underlying benign meningioma.
  • CONCLUSIONS: Although rare, neurosurgeons should be aware of the entity of tumor-to-tumor metastasis as, in large series, meningiomas are the third most frequent recipient tumor type and pituitary adenomas, the fifth most frequent, probably reflecting their rich vascularity.
  • [MeSH-major] Brain Edema / etiology. Image Processing, Computer-Assisted. Lymphoma, B-Cell, Marginal Zone / diagnosis. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Meningioma / diagnosis. Multiple Myeloma / diagnosis. Multiple Myeloma / secondary. Neoplasms, Second Primary / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Brain / pathology. Brain / surgery. Diagnosis, Differential. Female. Humans. Male. Meninges / pathology. Meninges / surgery. Middle Aged

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21300009.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Raitila A, Georgitsi M, Karhu A, Tuppurainen K, Mäkinen MJ, Birkenkamp-Demtröder K, Salmenkivi K, Orntoft TF, Arola J, Launonen V, Vahteristo P, Aaltonen LA: No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr Relat Cancer; 2007 Sep;14(3):901-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene were recently observed in patients with pituitary adenoma predisposition (PAP).
  • Though AIP mutation-positive individuals with prolactin-, mixed growth hormone/prolactin-, and ACTH-producing pituitary adenomas as well as non-secreting pituitary adenomas have been reported, most mutation-positive patients have had growth hormone-producing adenomas diagnosed at relatively young age.
  • Pituitary adenomas are also component tumors of some familial endocrine neoplasia syndromes such as multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC).
  • Genes underlying MEN1 and CNC are rarely mutated in sporadic pituitary adenomas, but more often in other lesions contributing to these two syndromes.
  • Thus far, the occurrence of somatic AIP mutations has not been studied in endocrine tumors other than pituitary adenomas.
  • Here, we have analyzed 32 pituitary adenomas and 79 other tumors of the endocrine system for somatic AIP mutations by direct sequencing.
  • However, two out of nine patients with prolactin-producing adenoma were shown to harbor a Finnish founder mutation (Q14X) with a complete loss of the wild-type allele in the tumors.
  • These results are in agreement with previous studies in that prolactin-producing adenomas are component tumors in PAP.
  • The data also support the previous finding that somatic AIP mutations are not common in pituitary adenomas and suggest that such mutations are rare in other endocrine tumors as well.
  • [MeSH-major] Adenoma / genetics. Carcinoma / genetics. Endocrine Gland Neoplasms / genetics. Mutation. Proteins / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914118.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Proteins; 0 / aryl hydrocarbon receptor-interacting protein
  •  go-up   go-down


29. Lee JI, Cho WH, Choi BK, Cha SH, Song GS, Choi CH: Delayed hyponatremia following transsphenoidal surgery for pituitary adenoma. Neurol Med Chir (Tokyo); 2008;48(11):489-92; discussion 492-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed hyponatremia following transsphenoidal surgery for pituitary adenoma.
  • The mean sodium level of symptomatic patients with hyponatremia at diagnosis was 123.5 mEq/l, compared with 129.8 mEq/l of asymptomatic patients.
  • [MeSH-major] Adenoma / surgery. Hyponatremia / etiology. Hypophysectomy / methods. Pituitary Neoplasms / surgery. Postoperative Complications / etiology


30. Murakami H, Nigawara T, Sakihara S, Kageyama K, Yamashita M, Matsuki K, Tanabe J, Matsui J, Tamasawa N, Suda T: The frequency of type 2 diabetic patients who meet the endocrinological screening criteria of subclinical Cushing's disease. Endocr J; 2010;57(3):267-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since a considerable percentage of pituitary adenomas causing overt Cushing's disease are not identifiable in magnetic resonance imaging, many of those causing subCD may also be unidentifiable.
  • Further follow-up studies including confirmatory testing and pituitary imaging are necessary.
  • [MeSH-major] Adrenocorticotropic Hormone / blood. Diabetes Mellitus, Type 2 / diagnosis. Hydrocortisone / blood
  • [MeSH-minor] Adult. Aged. Circadian Rhythm. Cushing Syndrome / diagnosis. Female. Humans. Male. Middle Aged. Pituitary ACTH Hypersecretion / diagnosis. Pituitary ACTH Hypersecretion / epidemiology

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20086312.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


31. Nielsen EH, Lindholm J, Laurberg P, Bjerre P, Christiansen JS, Hagen C, Juul S, Jørgensen J, Kruse A, Stochholm K: Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary; 2007;10(1):67-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function.
  • The incidence of clinically significant, nonfunctioning pituitary adenoma, requiring surgical treatment, has not been established.
  • According to previous studies, both surgery type and subsequent radiotherapy may have an impact on quality of life (QOL), and some studies have shown increased cardiovascular mortality in patients with pituitary disease.
  • We studied all patients with functionless, suprasellar pituitary adenoma who were operated on during the period 1985-1996 (N = 192; transsphenoidal surgery = 160, craniotomy = 32).
  • Postoperatively, 27% of the patients had normal pituitary function and 27% were panhypopituitary.
  • Death from cardiovascular, cerebrovascular and malignant diseases was not increased.
  • [MeSH-major] Adenoma / mortality. Pituitary Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1420-5 [10770176.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2093-9 [16522693.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3306-12 [15240607.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3364-9 [16787991.001]
  • [Cites] Pituitary. 2003 Sep;6(2):81-7 [14703017.001]
  • [Cites] Lancet. 1990 Aug 4;336(8710):285-8 [1973979.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Apr;46(4):445-50 [9196607.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Apr;46(4):401-6 [9196600.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Mar;50(3):315-9 [10435056.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Dec;57(6):713-7 [12460319.001]
  • [Cites] J Endocrinol Invest. 2005 Oct;28(9):787-94 [16370556.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3337-41 [15755865.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):613-9 [15274075.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jan;46(1):75-81 [9059561.001]
  • [Cites] J Affect Disord. 2001 Oct;66(2-3):159-64 [11578668.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Jul;63(1):103-10 [15963069.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):117-23 [11231987.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3279-86 [15741267.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75 [16968795.001]
  • [Cites] Lancet. 2001 Feb 10;357(9254):425-31 [11273062.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):1169-72 [8772595.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Jul;65(1):51-8 [16817819.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Mar;64(3):319-22 [16487443.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1621-34 [16636129.001]
  • (PMID = 17356906.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Mou C, Han T, Zhao H, Wang S, Qu Y: Clinical features and immunohistochemical changes of pituitary apoplexy. J Clin Neurosci; 2009 Jan;16(1):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and immunohistochemical changes of pituitary apoplexy.
  • The clinical features of 426 pituitary adenomas were retrospectively analyzed, focusing on the factors that affect the development of pituitary apoplexy.
  • Immunohistochemical analysis was used to define the different hormone types of the tumors and the expression of various immunologic targets, including the pituitary tumor transforming gene, basic fibroblast growth factor-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and proliferating cell nuclear antigen.
  • Of the 426 patients, 83 presented with pituitary apoplexy (19.48%).
  • Clinical manifestations included headaches (80/83, 96.38%), vision loss (69/83, 83.13%), pituitary function change (51/83, 61.45%), visual field defects (41/83, 49.39%), and nausea and vomiting (34/83, 40.96%).
  • Male patients and patients with functional adenoma had a higher probability of developing apoplexy.
  • Complicated immunological expression patterns were found in adenomas associated with pituitary apoplexy, with adenomas of different hormone types identified.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / physiology. Growth Hormone / metabolism. Matrix Metalloproteinase 9 / metabolism. Pituitary Apoplexy / metabolism. Proliferating Cell Nuclear Antigen / metabolism
  • [MeSH-minor] Adenoma / complications. Adult. Disease Progression. Female. Humans. Male. Middle Aged. Pituitary Neoplasms / complications. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046883.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 9002-72-6 / Growth Hormone; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


33. Carrim ZI, Reeks GA, Chohan AW, Dunn LT, Hadley DM: Predicting impairment of central vision from dimensions of the optic chiasm in patients with pituitary adenoma. Acta Neurochir (Wien); 2007 Mar;149(3):255-60; discussion 260
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting impairment of central vision from dimensions of the optic chiasm in patients with pituitary adenoma.
  • AIM: To study a possible relationship between dimensions of the optic chiasm and extent of visual field impairment in patients with pituitary adenoma.
  • METHODS: Pre-operative magnetic resonance (MR) scans and Goldmann perimetry charts of patients having undergone resection of a pituitary adenoma were retrieved.
  • [MeSH-major] Adenoma / complications. Nerve Compression Syndromes / etiology. Optic Chiasm / pathology. Optic Nerve Diseases / etiology. Pituitary Neoplasms / complications. Postoperative Complications / etiology. Vision, Low / etiology. Visual Fields / physiology


34. Er U, Gürses L, Saka C, Belen D, Yiğitkanli K, Simşek S, Akin I, Bavbek M: Sublabial transseptal approach to pituitary adenomas with special emphasis on rhinological complications. Turk Neurosurg; 2008 Oct;18(4):425-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sublabial transseptal approach to pituitary adenomas with special emphasis on rhinological complications.
  • OBJECTIVE: The aim of this presentation is to show that the sublabial transseptal transsphenoidal approach to pituitary adenomas is the least invasive anatomic route with the lowest postoperative complication rates.
  • PATIENTS AND METHOD: This study was based on a retrospective analysis of 276 patients with a diagnosis of pituitary adenoma who were surgically treated via the sublabial transsphenoidal route.
  • [MeSH-major] Adenoma / surgery. Neurosurgical Procedures / methods. Nose Diseases / epidemiology. Nose Diseases / etiology. Pituitary Neoplasms / surgery. Postoperative Complications / epidemiology
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / surgery. Adult. Aged. Diabetes Insipidus / epidemiology. Diabetes Insipidus / etiology. Female. Growth Hormone-Secreting Pituitary Adenoma / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nasal Mucosa / injuries. Nasal Mucosa / pathology. Nasal Septum / injuries. Nasal Septum / pathology. Neoplasm Recurrence, Local / epidemiology. Prolactinoma / surgery. Retrospective Studies. Thyrotropin / metabolism. Tomography, X-Ray Computed. Treatment Outcome. Water-Electrolyte Imbalance / epidemiology. Water-Electrolyte Imbalance / etiology. Young Adult


35. Chen L, Zhuang G, Li W, Liu Y, Zhang J, Tian X: RGD-FasL induces apoptosis of pituitary adenoma cells. Cell Mol Immunol; 2008 Feb;5(1):61-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RGD-FasL induces apoptosis of pituitary adenoma cells.
  • This study was to investigate the cytotoxic effects on pituitary adenoma cell lines GH3/MMQ/AtT20 induced by RGD-FasL and the underlying mechanism.
  • We concluded that RGD-FasL could possibly be considered as a novel therapeutical candidate for the treatment of pituitary adenomas.
  • [MeSH-major] Apoptosis. Fas Ligand Protein / metabolism. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318996.001).
  • [ISSN] 1672-7681
  • [Journal-full-title] Cellular & molecular immunology
  • [ISO-abbreviation] Cell. Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Fas Ligand Protein; 0 / Oligopeptides; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RANK Ligand; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human; 0 / TNFSF11 protein, human; 99896-85-2 / arginyl-glycyl-aspartic acid; EC 2.7.1.24 / Mitogen-Activated Protein Kinase 9; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC4072323
  •  go-up   go-down


36. Sheehan JM, Sheehan JP, Douds GL, Page RB: DDAVP use in patients undergoing transsphenoidal surgery for pituitary adenomas. Acta Neurochir (Wien); 2006 Mar;148(3):287-91; discussion 291
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DDAVP use in patients undergoing transsphenoidal surgery for pituitary adenomas.
  • BACKGROUND: Disorders of fluid and sodium regulation, often termed "diabetes insipidus," are a frequent occurrence following surgery for pituitary adenomas.
  • The present study was undertaken to identify the incidence of diabetes insipidus after pituitary surgery and its associated factors.
  • METHODS: A retrospective review of the medical records 300 patients who underwent transsphenoidal surgery for pituitary adenoma was undertaken.
  • Information regarding patient gender, perioperative serum sodium levels and urinary output volumes, tumor size, previous pituitary surgery, tumor subtype, and the use of DDAVP was gathered.
  • CONCLUSIONS: Transient hypotonic polyuria is frequently encountered after pituitary surgery.
  • [MeSH-major] Adenoma / drug therapy. Deamino Arginine Vasopressin / administration & dosage. Diabetes Insipidus / drug therapy. Pituitary Gland / drug effects. Pituitary Neoplasms / drug therapy. Postoperative Complications / drug therapy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Diabetes Insipidus.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. SODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362179.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antidiuretic Agents; 9NEZ333N27 / Sodium; ENR1LLB0FP / Deamino Arginine Vasopressin
  •  go-up   go-down


37. Mueller A, Gooren L: Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol; 2008 Sep;159(3):197-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recommendations for early diagnosis and prevention are presented.
  • RESULTS: In male-to-female transsexuals receiving estrogen administration, lactotroph adenomas, breast cancer, and prostate cancer have been reported.
  • The probability of a hormone-related tumor increases with the duration of exposure to cross-sex hormones and the aging of the population of transsexuals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18567667.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  • [Number-of-references] 47
  •  go-up   go-down


38. Giavoli C, Ferrante E, Bergamaschi S, Ronchi CL, Lania AG, Spada A, Beck-Peccoz P: An unusual case of recurrent autoimmune hypophysitis. Exp Clin Endocrinol Diabetes; 2010 May;118(5):287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autoimmune hypophysitis (AH) is an inflammatory disease that can present either as empty sella or as pituitary mass.
  • A pituitary MRI performed 2 years before for severe headache demonstrated a large sellar and suprasellar lesion.
  • Four years later, severe headache and a MRI suggestive of pituitary adenoma recurred.
  • A MRI performed 3 months later did not show any pituitary lesion and empty sella was again described.
  • This patient represents one of the few reported cases of recurrent hypophysitis and demonstrates that both pituitary enlargement and empty-sella can be seen in the same patient at different times of his history.
  • [MeSH-major] Pituitary Diseases / radiography
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Amenorrhea / etiology. Autoimmune Diseases / pathology. Empty Sella Syndrome / pathology. Female. Human Growth Hormone / therapeutic use. Humans. Hypogonadism / drug therapy. Hypopituitarism / pathology. Pituitary Neoplasms / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pituitary Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691013.001).
  • [ISSN] 1439-3646
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


39. Tanriverdi F, Karaca Z, Oner A, Durak AC, Selcuklu A, Unluhizarci K, Kelestimur F: Complete surgical resolution of bilateral total opthalmoplegia without visual field defect in an acromegalic patient presented with pituitary apoplexy. Endocr J; 2007 Dec;54(5):681-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete surgical resolution of bilateral total opthalmoplegia without visual field defect in an acromegalic patient presented with pituitary apoplexy.
  • Pituitary apoplexy (PA), which is one of the most serious life-threatening complications of pituitary adenoma, is characterized by abrupt onset of headache, nausea, vomiting, visual disturbances and oculomotor paresis.
  • MRI showed a large heterogeneous mass in the pituitary fossa.
  • The patient underwent transsphenoidal excision of the pituitary mass.
  • Histological examination revealed an adenoma with large areas of hemorrhagic infarction and most of the cells were positive for GH in immunohistochemical analysis.
  • Therefore the presented case clearly demonstrates that opthalmoplegia without a visual field defect due to PA has a good prognosis and early diagnosis and treatment including surgical decompression are crucially important.
  • [MeSH-major] Acromegaly / complications. Ophthalmoplegia / complications. Ophthalmoplegia / surgery. Pituitary Apoplexy / complications. Visual Fields / physiology
  • [MeSH-minor] Humans. Hypopituitarism / etiology. Male. Middle Aged. Pituitary Neoplasms / complications. Pituitary Neoplasms / surgery. Vision, Ocular / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785921.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Nishiyama S, Okudaira M, Saito N: Mechanisms of rolipram-induced increase in the incidence of mammary adenocarcinoma: histopathological study of a 104-week oral carcinogenicity study in female Sprague-Dawley rats. Arch Toxicol; 2006 Feb;80(2):88-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of rolipram-induced increase in the incidence of mammary adenocarcinoma: histopathological study of a 104-week oral carcinogenicity study in female Sprague-Dawley rats.
  • To clarify the mechanisms behind a rolipram-induced increase in the incidence of mammary adenocarcinoma at time points earlier than 104 weeks, the hormonal changes associated with pituitary adenoma were identified, and estrous cycling in the ovary, uterus, and vagina were examined in female rats treated with rolipram for 52 weeks.
  • There was also a dose-dependent relationship with PRL-producing pituitary adenomas.
  • Together, all of the above mentioned data suggest that rolipram not only stimulates an increase in the number and size of PRL adenomas in the pituitary gland but also in the estrus phase of the estrous cycle.
  • These events might cause progression of the mammary gland tissues from hyperplasia to carcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Mammary Neoplasms, Experimental / chemically induced. Phosphodiesterase Inhibitors / toxicity. Pituitary Neoplasms / chemically induced. Prolactinoma / chemically induced. Rolipram / toxicity

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167140.001).
  • [ISSN] 0340-5761
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Phosphodiesterase Inhibitors; 4TI98Z838E / Estradiol; 9002-62-4 / Prolactin; K676NL63N7 / Rolipram
  •  go-up   go-down


41. Brzezińska B, Junik R, Kamińska A, Zieliński G: [Difficulties in the diagnosis of ACTH-dependent Cushing's syndrome in a patient after left adrenalectomy and treated with glucocorticoids]. Endokrynol Pol; 2009 Nov-Dec;60(6):484-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Difficulties in the diagnosis of ACTH-dependent Cushing's syndrome in a patient after left adrenalectomy and treated with glucocorticoids].
  • Corticotropin secreting pituitary adenomas are responsible for most cases of endogenous Cushing' s syndrome.
  • Difficulties in the diagnosis and treatment of ACTH-dependent Cushing's syndrome concern with localization of the source of pathological ACTH secretion, particularly when magnetic resonance imaging is unable to identify the pituitary microadenoma.
  • In this paper we present the case of a patient with symptoms of Cushing's syndrome and describe problems with localization of the source of hypercortisolemia.
  • The diagnostic process was additionally complicated by the treatment with corticosteroids, occasionally applied due to concomitant diseases.
  • This delayed the right diagnosis and treatment.
  • [MeSH-major] Adrenocorticotropic Hormone / metabolism. Cushing Syndrome / diagnosis. Cushing Syndrome / etiology
  • [MeSH-minor] Adrenalectomy. Adult. Delayed Diagnosis. Female. Glucocorticoids / adverse effects. Glucocorticoids / therapeutic use. Humans. Lumbar Vertebrae / injuries. Lumbar Vertebrae / surgery. Methylprednisolone / adverse effects. Methylprednisolone / therapeutic use. Prednisone / adverse effects. Prednisone / therapeutic use. Spinal Fractures / complications. Spinal Fractures / surgery. Thoracic Vertebrae / injuries. Thoracic Vertebrae / surgery

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20041367.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Glucocorticoids; 9002-60-2 / Adrenocorticotropic Hormone; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


42. Conte-Devolx B, Niccoli P, Groupe d'étude des Tumeurs Endocrines: [Clinical characteristics of multiple endocrine neoplasia]. Bull Acad Natl Med; 2010 Jan;194(1):69-78; discussion 78-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple endocrine neoplasia type 1 (MEN1) and type 2 (MEN2) are autosomal dominant inherited multiglandular diseases with familial and individual age-related penetrance and variable expression.
  • The most frequent endocrine features of MEN1 are parathyroid involvement (> 95%), duodeno-pancreatic endocrine tissue involvement (80%), pituitary adenoma (30%), and adrenal cortex tumors (25%), with no clear syndromic variants.
  • Identification of the germline MEN1 mutation confirms the diagnosis, but there is no phenotype-genotype correlation.
  • The prognosis of MEN2 is linked to the progression of MTC, which depends mainly on the stage at diagnosis and the quality of initial surgical treatment.
  • This emphasizes the need for early diagnosis and management.
  • [MeSH-minor] Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / surgery. Adrenalectomy. Carcinoma, Medullary / genetics. Carcinoma, Medullary / surgery. Digestive System Neoplasms / genetics. Digestive System Neoplasms / surgery. Early Diagnosis. Genes, Tumor Suppressor. Genetic Testing. Humans. Pheochromocytoma / genetics. Pheochromocytoma / surgery. Thyroid Neoplasms / genetics. Thyroid Neoplasms / surgery. Thyroidectomy

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669560.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 29
  •  go-up   go-down


43. Kumar P, Kumar P, Singh S, Kumari N, Datta NR: Chordoma with increased prolactin levels (pseudoprolactinoma) mimicking pituitary adenoma: a case report with review of the literature. J Cancer Res Ther; 2009 Oct-Dec;5(4):309-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chordoma with increased prolactin levels (pseudoprolactinoma) mimicking pituitary adenoma: a case report with review of the literature.
  • It could often result in a diagnostic dilemma and problems in differentiating it from a pituitary adenoma.
  • [MeSH-major] Chordoma / metabolism. Chordoma / pathology. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / pathology. Prolactin / blood

  • Genetic Alliance. consumer health - Chordoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20160370.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 9002-62-4 / Prolactin
  • [Number-of-references] 10
  •  go-up   go-down


44. Brito LP, Lerário AM, Bronstein MD, Soares IC, Mendonca BB, Fragoso MC: Influence of the fibroblast growth factor receptor 4 expression and the G388R functional polymorphism on Cushing's disease outcome. J Clin Endocrinol Metab; 2010 Oct;95(10):E271-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Abnormal FGFR4 expression has been detected in pituitary tumors, especially in larger and invasive adenomas.
  • [MeSH-major] Pituitary ACTH Hypersecretion / genetics. Polymorphism, Single Nucleotide. Receptor, Fibroblast Growth Factor, Type 4 / genetics
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / diagnosis. ACTH-Secreting Pituitary Adenoma / genetics. ACTH-Secreting Pituitary Adenoma / surgery. Adolescent. Adult. Amino Acid Substitution / genetics. Arginine / genetics. Child. Female. Gene Expression / physiology. Glycine / genetics. Humans. Hypophysectomy. Male. Middle Aged. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / genetics. Pituitary Neoplasms / surgery. Prognosis. Recurrence. Retrospective Studies. Treatment Outcome. Young Adult

  • Hazardous Substances Data Bank. GLYCINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660043.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 94ZLA3W45F / Arginine; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 4; TE7660XO1C / Glycine
  •  go-up   go-down


45. Ławnicka H, Pisarek H, Kunert-Radek J, Pawlikowski M: Effects of somatostatin on vascular endothelial growth factor (VEGF) secretion from non-functioning pituitary tumoral cells incubated in vitro. Neuro Endocrinol Lett; 2008 Feb;29(1):113-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of somatostatin on vascular endothelial growth factor (VEGF) secretion from non-functioning pituitary tumoral cells incubated in vitro.
  • OBJECTIVES: The aim of the study was to examine the effect of somatostatin (SST) on vascular endothelial growth factor (VEGF) secretion from clinically non-functioning pituitary tumors incubated in vitro.
  • MATERIAL AND METHODS: Eight pituitary tumors surgically removed were investigated.
  • Seven of them were diagnosed after surgery as pituitary adenomas and expressed either gonadotropins or their subunits as detected by immunohistochemistry.
  • One tumor was immunonegative for pituitary hormones and was diagnosed as haemangiopericytoma.
  • CONCLUSIONS: The response of VEGF secretion from pituitary tumoral cells to SST seems to depend on the spectrum of expressed somatostatin receptor subtypes.
  • [MeSH-major] Adenoma / metabolism. Pituitary Neoplasms / metabolism. Somatostatin / pharmacology. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283262.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 0 / Vascular Endothelial Growth Factor A; 51110-01-1 / Somatostatin; 9002-62-4 / Prolactin; 9002-72-6 / Growth Hormone
  •  go-up   go-down


46. Fedele M, Fusco A: HMGA and cancer. Biochim Biophys Acta; 2010 Jan-Feb;1799(1-2):48-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, HMGA dysregulation, as a result of specific chromosomal rearrangements, occurs in a broad variety of common benign mesenchymal tumors, making HMGA genes among the most commonly rearranged genes in human neoplasms.
  • Nevertheless, recent data propose a critical role of HMGA overexpression also in the generation of pituitary adenomas.
  • Here, we review the involvement of HMGA proteins in cancer, analyzing the mechanisms underlying their crucial role in tumorigenesis, and, finally, discuss the potentiality of a cancer treatment based on HMGA targeting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 20123067.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / HMGA Proteins
  • [Number-of-references] 121
  •  go-up   go-down


47. Pegvisomant: new preparation. A last resort in acromegaly. Prescrire Int; 2005 Feb;14(75):10-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An increase in the size of the pituitary adenoma, due to the resulting hyperfunctioning, was observed in four of the 160 patients treated in clinical trials. (5) Evaluation data on pegvisomant does not resolve the question of possible hepatic toxicity. (6) In practice, pegvisomant therapy is justified for patients with serious complications of acromegaly and who have no other treatment options.
  • [MeSH-minor] Adenoma / surgery. Drug Approval. Europe. Humans. Octreotide / administration & dosage. Octreotide / adverse effects. Octreotide / therapeutic use. Randomized Controlled Trials as Topic. Somatostatin / administration & dosage. Somatostatin / adverse effects. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751152.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


48. Mantovani G, Lania AG, Spada A: GNAS imprinting and pituitary tumors. Mol Cell Endocrinol; 2010 Sep 15;326(1-2):15-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GNAS imprinting and pituitary tumors.
  • Evidence from in vitro studies and naturally occurring human diseases indicate that several endocrine cells, and particularly somatotrophs, recognize cAMP as a growth factor.
  • Accordingly, mutations of the alpha subunit of the stimulatory G protein gene (GNAS) leading to the constitutive activation of adenylyl cyclase (the so-called gsp oncogene) have been found in a significant proportion of GH-secreting pituitary adenomas.
  • This complex tissue-specific imprinting control results in a near-exclusive expression of Gsalpha from the maternal allele in specific endocrine tissues, including the pituitary.
  • Due to the monoallelic origin of Gsalpha in normal pituitary gsp mutations occur on a maternal allele in order to have a phenotypic effect in both sporadic GH-secreting adenomas and those associated with the McCune-Albright syndrome.
  • Therefore, genetic and epigenetic alterations of the GNAS gene, with subsequent dysregulation of the cAMP pathway, appear, to date, the only molecular hallmark of most GH-secreting adenomas.
  • [MeSH-major] GTP-Binding Protein alpha Subunits, Gs / genetics. Pituitary Neoplasms / genetics
  • [MeSH-minor] Animals. Cyclic AMP-Dependent Protein Kinases / metabolism. Fibrous Dysplasia, Polyostotic / genetics. Genomic Imprinting. Growth Hormone-Secreting Pituitary Adenoma / genetics. Humans. Mice. Pituitary Gland / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20398730.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.6.1.- / GNAS protein, human; EC 3.6.1.- / Gnas protein, mouse; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


49. Liu W, Matsumoto Y, Okada M, Miyake K, Kunishio K, Kawai N, Tamiya T, Nagao S: Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J Med Invest; 2005 Aug;52(3-4):151-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas.
  • The aim of this study is to evaluate the relationship between the expression of MMP-2, MMP-9, MIB-1 LI and cavernous sinus invasion in pituitary adenomas.
  • METHODS: Tissue samples from 54 patients with pituitary adenomas were studied.
  • The MIB-1 LI of this study presented no significantly difference between the invasive and noninvasive pituitary adenomas.
  • The percentage of MMP-2 mRNA/beta-actin mRNA and MMP-9 mRNA/beta-actin mRNA were also observed significantly higher in invasive pituitary adenomas (68.2 +/- 15.3%; 59.7 +/- 12.5%) than noninvasive pituitary adenomas (21.8 +/- 8.2%, p < 0.05; 33.3 +/- 5.4%, p < 0.05).
  • CONCLUSIONS: Our study suggests that the expression of MMP-2 and MMP-9 may have a value to assess the invasive pituitary adenomas, and proliferation and invasion of pituitary adenomas may present a different mechanism.
  • [MeSH-major] Adenoma / enzymology. Cavernous Sinus. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Pituitary Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167532.001).
  • [ISSN] 1343-1420
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


50. Rokni-Yazdi H, Azmoudeh Ardalan F, Asadzandi Z, Sotoudeh H, Shakiba M, Adibi A, Ayatollahi H, Rahmani M: Pathologic significance of the "dural tail sign". Eur J Radiol; 2009 Apr;70(1):10-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 30 cases, "dural tail sign" was evident on MRI, dural tail noted in 17 of these cases in histological samples (12 meningiomas, 3 pituitary adenomas and 2 schwannomas).

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294796.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


51. Estepa A, Dastis M, Alia P, Boluda S, Angel Navarro M, José Acebes J, Soler J, Villabona C: Utility of alpha subunit determination after thyrotropin-releasing hormone stimulation as an indicator of gonadotropinoma persistence and/or recurrence. Endocrinol Nutr; 2008 Jun;55(6):253-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Gonadotropinomas are adenomas of the gonadotropic cells of the anterior pituitary.
  • SUBJECTS AND METHOD: We studied 24 patients with pituitary macroadenoma, 14 of who had a histological diagnosis of gonadotroph adenoma.
  • CONCLUSIONS: This test could be useful in the differential diagnosis of gonadotropinomas as well as in the follow-upand postsurgical evaluation of these tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Sociedad Española de Endocrinología y Nutrición. Published by Elsevier Espana. All rights reserved.
  • (PMID = 22964125.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


52. Lytras A, Tolis G: Growth hormone-secreting tumors: genetic aspects and data from animal models. Neuroendocrinology; 2006;83(3-4):166-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inactivation of the MEN1 gene appears to be only rarely associated with sporadic pituitary tumor development.
  • PRKAR1A mutations are infrequently associated with sporadic GH-secreting adenomas.
  • [MeSH-minor] Animals. Chromosome Mapping. Cyclic AMP-Dependent Protein Kinase RIalpha Subunit. Disease Models, Animal. Endocrine Gland Neoplasms / genetics. Endocrine Gland Neoplasms / metabolism. Humans. Multiple Endocrine Neoplasia Type 1 / genetics. Multiple Endocrine Neoplasia Type 1 / metabolism. Pituitary Neoplasms / genetics. Pituitary Neoplasms / metabolism. Syndrome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047380.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / MEN1 protein, human; 0 / PRKAR1A protein, human; 0 / Proto-Oncogene Proteins; 12629-01-5 / Human Growth Hormone; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases
  • [Number-of-references] 94
  •  go-up   go-down


53. Muto S, Kasahara H, Yokoi R, Hayashi M, Souma S, Kobayashi K, Tamura T, Murakami M, Kuroda J, Shibata N: [Toxicity profile of silodosin (KMD-3213)]. Yakugaku Zasshi; 2006 Mar;126 Spec no.:247-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Repeated-dose studies revealed fatty degeneration of hepatocytes and an induction of drug-metabolizing enzymes at 15 mg/kg/day or more in male rats, mammary gland hyperplasia at 60 mg/kg/day or more in female rats, and degeneration of the seminiferous tubular epithelium at 25 mg/kg/day or more only in young dogs.
  • Silodosin was negative in all mutagenicity studies, except for a weak positive in a chromosomal aberration assay conducted without metabolic activation.
  • In carcinogenicity studies, mammary gland tumors and pituitary adenomas were increased in female mice given 150 mg/kg/day or more and 400 mg/kg/day respectively, while thyroid follicular cell carcinoma was increased in male rats given 150 mg/kg/day.
  • As a new therapeutic drug for the micturition difficulties caused by benign prostatic hyperplasia, silodosin should have few serious side effects in clinical use.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518090.001).
  • [ISSN] 0031-6903
  • [Journal-full-title] Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • [ISO-abbreviation] Yakugaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Indoles; CUZ39LUY82 / silodosin
  •  go-up   go-down


54. Hou XZ, Liu W, Fan HT, Liu B, Pang B, Xin T, Xu SC, Pang Q: Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas. Neuro Oncol; 2010 Aug;12(8):799-803
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.
  • But little is known about their expression in pituitary adenomas.
  • In this study, the expression of HGF and c-Met in pituitary adenomas of different histology types was investigated by immunohistochemistry, and correlative analysis of their expression with microvessel density (MVD), Ki-67 expression, and other clinicopathologic factors was made.
  • The results showed that the expression of HGF and c-Met exists in 98% (64 of 65) and 92% (60 of 65) pituitary adenomas, respectively, and co-expression of them existed in 91% (59 of 65) adenomas.
  • There were no significant differences in HGF and c-Met expression between pituitary adenomas of different histology types.
  • The results indicate that HGF and c-Met are widely expressed in pituitary adenomas, and their expression correlates with MVD and Ki-67 expression.
  • [MeSH-major] Adenoma / metabolism. Adenoma / pathology. Hepatocyte Growth Factor / biosynthesis. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / pathology. Proto-Oncogene Proteins c-met / biosynthesis


55. Zhang X, Fei Z, Zhang W, Cao WD, Liu WP, Zhang JN, Fu LA, Jiang XF, Zhen HN, Song SJ, Li X: Emergency transsphenoidal surgery for hemorrhagic pituitary adenomas. Surg Oncol; 2007 Aug;16(2):115-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergency transsphenoidal surgery for hemorrhagic pituitary adenomas.
  • Hemorrhagic pituitary adenoma (HPA) is an acute clinical event in neurosurgery.
  • The majority of the patients (81.5%) experienced the acute symptoms of pituitary apoplexy including headache, ocular paresis, visual field deficits and hypopituitarism.
  • On imaging features, 34 adenomas (52.3%) showed marked suprasellar extension, 17 (26.2%) showed moderate extension, and 6 (9.2%) had slight extension, another eight (12.3%) were intrasellar.
  • [MeSH-major] Adenoma / therapy. Emergencies. Hemorrhage / surgery. Pituitary Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17643985.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


56. Choe JH, Lee KS, Jeun SS, Cho JH, Hong YK: Endocrine outcome of endoscopic endonasal transsphenoidal surgery in functioning pituitary adenomas. J Korean Neurosurg Soc; 2008 Sep;44(3):151-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine outcome of endoscopic endonasal transsphenoidal surgery in functioning pituitary adenomas.
  • OBJECTIVE: Microscopic and endoscopic transsphenoidal approach (TSA) are major surgical techniques in the treatment of pituitary adenoma.
  • Endoscopic endonasal transsphenoidal approach (EETSA) has been increasingly used for pituitary adenomas, however, its surgical outcome particularly in functioning pituitary adenoma has been debated.
  • Here, we investigated the endocrine outcome of the patients with growth hormone (GH) and adrenocorticotropic hormone (ACTH) secreting pituitary adenoma treated by EETSA.
  • METHODS: We treated 80 patients with pituitary adenoma by EETSA since 2004, of which 12 patients were affected by functioning pituitary adenomas (9 GH, 3 ACTH, 0 PRL; 9 macro, 3 micro).
  • Surgical outcome of those patients treated by EETSA was compared with that of the 11 functioning pituitary adenoma patients (8 GH, 3 ACTH; 8 macro, 3 micro) who underwent sublabial microscopic TSA between 1997 and 2003.
  • CONCLUSION: EETSA appears to be an effective and safe method for the treatment of functioning pituitary adenomas.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Rhinol. 2007 Jul-Aug;21(4):510-4 [17882925.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1645-52 [11297598.001]
  • [Cites] Am J Rhinol. 2007 Mar-Apr;21(2):203-6 [17424881.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):240-8 [17047389.001]
  • [Cites] Neurosurgery. 2005 Jun;56(6):1222-33; discussion 1233 [15918938.001]
  • [Cites] Eur J Endocrinol. 2005 Mar;152(3):379-87 [15757854.001]
  • [Cites] Surg Neurol. 1997 Mar;47(3):213-22; discussion 222-3 [9068690.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):189-92; discussion 192-3 [8805160.001]
  • [Cites] J Laryngol Otol. 1994 Jan;108(1):19-22 [8133158.001]
  • [Cites] Laryngoscope. 1992 Feb;102(2):198-202 [1738293.001]
  • [Cites] J Clin Endocrinol Metab. 1988 May;66(5):1056-64 [3360898.001]
  • [Cites] Neurosurgery. 1987 Aug;21(2):218-22 [2821447.001]
  • [Cites] Clin Neurosurg. 1969;16:185-217 [5811707.001]
  • [Cites] Surg Neurol. 2002 Dec;58(6):371-5; discussion 375-6 [12517610.001]
  • [Cites] J Neurooncol. 2001 Sep;54(2):187-95 [11761435.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4072-7 [11549628.001]
  • [Cites] Laryngoscope. 2007 Aug;117(8):1329-32 [17597634.001]
  • (PMID = 19096666.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588303
  • [Keywords] NOTNLM ; ACTH-secreting pituitary adenoma / Endoscopy / GH-secreting pituitary adenoma / Transsphenoidal approach
  •  go-up   go-down


57. Heljić B, Bureković A, Iglica A: [Evaluation of the tumor of the pituitary gland (hypophysis) between 2000-2005. On the intensive care of The Endocrinology Clinic of the Clinical Center of the University of Sarajevo]. Med Arh; 2006;60(3):175-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the tumor of the pituitary gland (hypophysis) between 2000-2005. On the intensive care of The Endocrinology Clinic of the Clinical Center of the University of Sarajevo].
  • INTRODUCTION: Tumors of the pituitary gland can be adenomas, and more often, cancers, representing 10-15% of intracranial neoplasm.
  • The goal of the research was to reveal the presence of tumors of the pituitary gland in the period 2000-2005 among patients hospitalized on the Intensive Care of the Endocrinology Clinic.
  • PATIENTS AND METHODS: Data from anamnesis of all patients with verified tumor of the pituitary gland between 2000.
  • RESULTS: Total number of patients with the tumor of pituitary gland was 40, 29 women and 11 men, and 35 % of patients were aged between 45 and 60.
  • There were 23 (57,5%) cases of micro adenoma and 17 (42,5 %) macro adenomas.
  • From the total number of patients 23 were operated, 8 micro adenomas and 15 macro adenomas.
  • The number of secreting adenomas was 25 (62,5 %) and 15 (37,5 %) were non-secreting.
  • Secreting adenomas were: prolactinomas--14, acromegalies -7, Cushing syndromes -2, TSH producing -2.
  • Non-secreting adenomas were: craniopharyngeomas--11, meningiomas -2, and 2 non-secreting micro adenomas.
  • 6 cases of acromegaly were operated and 1 micro adenoma is still under medical supervision, with the therapy of bromocriptine.
  • 1 case of TSH producing tumor was operated, but residuum and hyperthyroidism are still presents, and the micro adenoma, for the hyperplasia reason, disappeared with adequate substitution therapy.
  • CONCLUSION: Tumors of the pituitary gland we mainly treat applying surgery methods, together with post operational substitution therapy or additional therapy with drugs.
  • [MeSH-major] Pituitary Neoplasms

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719232.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] bos
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


58. Batista D, Courkoutsakis NA, Oldfield EH, Griffin KJ, Keil M, Patronas NJ, Stratakis CA: Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with cushing disease. J Clin Endocrinol Metab; 2005 Sep;90(9):5134-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with cushing disease.
  • CONTEXT: We recently showed that pre- and postcontrast spoiled gradient-recalled acquisition in the steady-state (SPGR) was superior to conventional pre- and postcontrast T-1 weighted spin echo (SE) acquisition magnetic resonance imaging (MRI) for the diagnostic evaluation of pituitary tumors in adult patients.
  • Postcontrast SPGR-MRI was superior to SE-MRI and should be used in addition to conventional SE-MRI in the pituitary evaluation of children and adolescents with suspected Cushing disease.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / secretion. Adrenocorticotropic Hormone / secretion. Cushing Syndrome / diagnosis. Magnetic Resonance Imaging. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / secretion

  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941871.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


59. Picard C, Silvy M, Gerard C, Buffat C, Lavaque E, Figarella-Branger D, Dufour H, Gabert J, Beckers A, Brue T, Enjalbert A, Barlier A: Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. Int J Cancer; 2007 Sep 15;121(6):1245-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment.
  • Gs alpha is paternally silenced in normal pituitary, but Gs alpha imprinting relaxation is found in some tumoral tissue.
  • In addition, Gs alpha mRNA levels are high in some somatotroph adenomas not bearing the active Gs alpha mutant, the gsp oncogene.
  • We compared the expression and imprinting of 4 transcripts of GNAS locus (NESP55, XL alpha s, exon 1A, Gs alpha) of 60 somatotroph adenomas with those of 23 lactotroph adenomas.
  • [MeSH-major] Adenoma / genetics. Drug Resistance, Neoplasm / genetics. GTP-Binding Protein alpha Subunits, Gs / genetics. Genomic Imprinting. Growth Hormone-Secreting Pituitary Adenoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17514647.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / RNA, Messenger; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs; RWM8CCW8GP / Octreotide
  •  go-up   go-down


60. Kadashev BA, Faĭzullaev RB, Kalinin PL, Kutin MA, Shkarubo AN, Alekseev SN, Fomichev DV, Grigor'eva NN, Tropinskaia OF: [Surgical treatment for giant pituitary adenomas: the state of visual functions]. Vestn Oftalmol; 2009 Mar-Apr;125(2):7-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment for giant pituitary adenomas: the state of visual functions].
  • Giant pituitary adenomas (more than 60 mm) are a most difficult group of tumors of the pituitary.
  • The most complete removal of a supracellular tumor portion irrespective of a chosen approach yields a better result than non-radical operations despite its potentially high traumaticity of visual nerves and optic chiasms.
  • [MeSH-major] Adenoma / surgery. Neurosurgical Procedures / methods. Optic Chiasm / physiopathology. Optic Nerve / physiopathology. Pituitary Neoplasms / surgery. Visual Acuity / physiology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Optic Nerve Diseases / etiology. Optic Nerve Diseases / physiopathology. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517822.001).
  • [ISSN] 0042-465X
  • [Journal-full-title] Vestnik oftalmologii
  • [ISO-abbreviation] Vestn Oftalmol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


61. Izumoto S, Arita N: [Treatment of pituitary adenomas: recent topics]. No Shinkei Geka; 2010 Jan;38(1):79-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pituitary adenomas: recent topics].
  • [MeSH-major] Pituitary Neoplasms / therapy
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / therapy. Female. Humans. Male. Prolactinoma / therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20085107.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 52
  •  go-up   go-down


62. Alexandraki KI, Grossman AB: Pituitary-targeted medical therapy of Cushing's disease. Expert Opin Investig Drugs; 2008 May;17(5):669-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary-targeted medical therapy of Cushing's disease.
  • BACKGROUND: The goals of ideal medical therapy for Cushing's disease should be to target the aetiology of the disorder, as is the case for surgery, which is the current 'gold standard' treatment.
  • However, no effective drug that directly and reliably targets the adrenocorticotropin-secreting pituitary adenoma has yet been found.
  • OBJECTIVE: To summarise pituitary-targeted medical treatment of Cushing's disease.
  • METHODS: Compounds with neuromodulatory properties and ligands of different nuclear hormone receptors involved in hypothalamo-pituitary regulation have been investigated.
  • CONCLUSION: Since a percentage of patients treated with surgery are not cured, or improve and subsequently relapse, there is an urgent need for effective medical therapies for this disorder.
  • [MeSH-major] Dopamine Agonists. Ergolines. Oligopeptides. Pituitary ACTH Hypersecretion / drug therapy. Pituitary Gland / drug effects. Somatostatin / analogs & derivatives

  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Expert Opin Investig Drugs. 2008 Jul;17(7):1141
  • (PMID = 18447593.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; 0 / Neurotransmitter Agents; 0 / Oligopeptides; 51110-01-1 / Somatostatin; 9002-60-2 / Adrenocorticotropic Hormone; 98H1T17066 / pasireotide; LL60K9J05T / cabergoline
  • [Number-of-references] 100
  •  go-up   go-down


63. Castro EC, Ferraz ML, Corrêa RR, Reis MA, Texeira VP: Cushing's disease in a 5-month infant due to a basophilic microadenoma of the pituitary gland. J Pediatr Endocrinol Metab; 2006 Oct;19(10):1263-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's disease in a 5-month infant due to a basophilic microadenoma of the pituitary gland.
  • We report a female patient who developed severe Cushing's disease during the fifth month of life due to a basophilic pituitary adenoma Histological findings showed a basophilic microadenoma of the pituitary gland, leading to the diagnosis of Cushing's disease.
  • The importance of the present report resides in the age of the child at diagnosis, and that it was the necropsy finding of microadenoma which clarified the cause of the Cushing's syndrome, since it was not diagnosed during life.
  • Cushing's disease is most often diagnosed in children older than 7 years, and our patient was only 5 months old when we detected the pituitary adenoma, the earliest case diagnosed so far.
  • Cushing's syndrome in pediatric patients has been rarely reported and most cases are due to functioning adrenal tumors, usually a malignant carcinoma but occasionally a benign adenoma.
  • The present case shows that the pituitary of these patients should be investigated with important implications in terms of therapeutic approaches, such as pituitary radiotherapy, which can cure the patient when treatment is started very soon.
  • [MeSH-major] Adenoma, Basophil / complications. Pituitary ACTH Hypersecretion / etiology. Pituitary Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172089.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


64. Fabiano AJ, Rigual NR, Belber CS, Fenstermaker RA: Endoscopic sellar floor reconstruction with concha bullosa bone autograft and nasal septal flap: technical case report. Minim Invasive Neurosurg; 2009 Apr;52(2):86-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain magnetic resonance imaging displayed a 1.2-cm pituitary adenoma.
  • The patient was diagnosed with acromegaly secondary to a pituitary adenoma and underwent expanded endoscopic endonasal transsphenoidal surgery for tumor resection.
  • Following adenoma resection, the sellar floor was reconstructed using concha bullosa bone autograft resected during the endonasal approach.
  • [MeSH-minor] Acromegaly / etiology. Acromegaly / surgery. Adenoma / pathology. Adenoma / surgery. Female. Growth Hormone / metabolism. Growth Hormone-Secreting Pituitary Adenoma / pathology. Growth Hormone-Secreting Pituitary Adenoma / surgery. Humans. Magnetic Resonance Imaging. Middle Aged. Nasal Cavity / anatomy & histology. Nasal Cavity / surgery. Nasal Mucosa / blood supply. Nasal Mucosa / surgery. Nasal Mucosa / transplantation. Neurosurgical Procedures / methods. Otorhinolaryngologic Surgical Procedures / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19452416.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Grant] United States / PHS HHS / / 55-08980-02
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


65. Goto J, Otsuka F, Inagaki K, Tsukamoto N, Suzuki J, Miyoshi T, Ogura T, Kamada Y, Makino H: Effects of growth hormone reduction in a patient with polycystic ovary syndrome complicated with acromegaly. Endocr J; 2009;56(1):157-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a rare case of polycystic ovary syndrome (PCOS) complicated with acromegaly due to a growth hormone (GH)-producing pituitary adenoma.
  • Complete removal of the pituitary adenoma successfully reduced circulating levels of GH and insulin-like growth factor (IGF)-1, which, in turn, resulted in the amelioration of gonadal dysfunction, hyperandrogenism, lutenizing hormone hypersecretion, and severe insulin resistance.
  • [MeSH-major] Acromegaly / complications. Adenoma / surgery. Growth Hormone / blood. Growth Hormone-Secreting Pituitary Adenoma / surgery. Polycystic Ovary Syndrome / complications

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840925.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


66. Lau KK, Joshi SM, Ellamushi H, Afshar F: Isolated bilateral oculomotor nerve palsy in pituitary apoplexy: case report and review. Br J Neurosurg; 2007 Aug;21(4):399-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated bilateral oculomotor nerve palsy in pituitary apoplexy: case report and review.
  • Pituitary tumours usually present with visual field defects; extraocular palsy is usually a sign of cavernous sinus extension and is a sign of advanced disease.
  • We report a case of a pituitary adenoma presenting with complete, bilateral oculomotor nerve palsies, but minimal loss of visual fields, and intact abducens and trochlear nerves.
  • [MeSH-major] Nerve Compression Syndromes / etiology. Oculomotor Nerve / surgery. Ophthalmoplegia / etiology. Pituitary Apoplexy / etiology. Pituitary Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17676462.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  •  go-up   go-down


67. Ulitin AIu, Oliushin VIu, Zhinzhina IV, Ovcharenko OIu, Getmanova VV, Markova NV: [Ophthalmological symptoms in patients with giant pituitary adenomas]. Vestn Oftalmol; 2007 May-Jun;123(3):36-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ophthalmological symptoms in patients with giant pituitary adenomas].
  • In patients with giant pituitary adenomas, visual dysfunction is a common complaint and the chiasmatic syndrome is the major clinical sign of the disease.
  • Early and timely diagnosis of a tumor in the absence of its extracellular growth makes it possible to improve visual function in the postoperative period and the quality of life.
  • [MeSH-major] Adenoma / complications. Pituitary Neoplasms / complications. Vision Disorders / etiology. Vision, Ocular / physiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672094.001).
  • [ISSN] 0042-465X
  • [Journal-full-title] Vestnik oftalmologii
  • [ISO-abbreviation] Vestn Oftalmol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


68. Nachtigall LB: Acromegaly diagnosed in a young woman presenting with headache and arthritis. Nat Clin Pract Endocrinol Metab; 2006 Oct;2(10):582-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An MRI scan revealed an 11-12 mm pituitary tumor.
  • Her physical examination was unremarkable for the classic acral or facial changes characteristic of acromegaly, and she was referred for neuroendocrine consultation for a presumed nonfunctioning adenoma.
  • INVESTIGATIONS: MRI of the pituitary, and laboratory investigations that included measurement of serum insulin-like growth factor 1 (IGF1) and prolactin levels.
  • DIAGNOSIS: In view of the elevated level of IGF1 and presence of a pituitary adenoma, the patient was diagnosed with acromegaly caused by a pituitary adenoma that secretes growth hormone.
  • [MeSH-major] Acromegaly / diagnosis. Arthritis, Rheumatoid / etiology. Headache / etiology
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / radiography. Adenoma / surgery. Adult. Algorithms. Female. Humans. Insulin-Like Growth Factor I / analysis. Magnetic Resonance Imaging. Pituitary Gland / abnormalities. Pituitary Gland / radiography. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / radiography. Pituitary Neoplasms / surgery

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Headache.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17024157.001).
  • [ISSN] 1745-8366
  • [Journal-full-title] Nature clinical practice. Endocrinology & metabolism
  • [ISO-abbreviation] Nat Clin Pract Endocrinol Metab
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I
  • [Number-of-references] 17
  •  go-up   go-down


69. Kim K, Yoshida D, Teramoto A: Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas. Endocr Pathol; 2005;16(2):115-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas.
  • Although VEGF and HIF-1alpha are expressed in pituitary adenomas, the relationships of these factors remain unclear.
  • Therefore, we examined the expression of HIF-1alpha and VEGF using real-time RT-PCR and immunohistochemistry to clarify the relationship of these factors in pituitary adenomas.
  • HIF-1alpha mRNA and VEGF mRNA levels in pituitary adenoma tissues from 25 operated patients were quantified using real-time RT-PCR.
  • HIF-1alpha mRNA and protein were expressed in all pituitary adenomas examined.
  • VEGF mRNA and protein were also expressed in all pituitary adenomas.
  • Our results suggest that in pituitary adenomas VEGF expression may not depend strongly on HIF-1alpha expression.
  • [MeSH-major] Adenoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Neurosci. 2003 May;10 (3):320-4 [12763337.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):236-43 [12539178.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] Pediatr Neurosurg. 2000 Jul;33(1):49-55 [11025423.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 8):36-41 [11395851.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5328-35 [9393757.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] Neuroendocrinology. 2001 Aug;74(2):95-105 [11474217.001]
  • [Cites] Acta Neuropathol. 1998 Nov;96(5):453-62 [9829808.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):55-9 [1984507.001]
  • [Cites] Am J Physiol. 1996 Oct;271(4 Pt 1):C1172-80 [8897823.001]
  • [Cites] Arch Histol Cytol. 1998 Mar;61(1):17-28 [9557964.001]
  • [Cites] Int J Radiat Biol. 2000 May;76(5):589-605 [10866281.001]
  • [Cites] Endocr Pathol. 1999 Autumn;10(3):229-235 [12114703.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):266-76 [11181773.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1138-43 [12615733.001]
  • [Cites] Ann Intern Med. 2003 Apr 15;138(8):659-68 [12693889.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1659-73 [9647657.001]
  • [Cites] Genes Dev. 1998 Jan 15;12(2):149-62 [9436976.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4238-44 [12213878.001]
  • [Cites] Int J Oncol. 2002 May;20(5):955-62 [11956589.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4757-9 [7585499.001]
  • [Cites] J Endocrinol Invest. 2003 Jan;26(1):23-8 [12602530.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jun;54(6):759-68 [11422110.001]
  • [Cites] J Endocrinol. 1999 Mar;160(3):483-90 [10076194.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Histol Histopathol. 2003 Jul;18(3):679-86 [12792878.001]
  • [Cites] Neurosurgery. 2003 Oct;53(4):880-5; discussion 885-6 [14519220.001]
  • [Cites] Curr Opin Genet Dev. 1998 Oct;8(5):588-94 [9794818.001]
  • [Cites] J Cell Physiol. 2003 Aug;196 (2):394-402 [12811834.001]
  • (PMID = 16199896.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


70. Suárez-Llanos JP, Fernández-Fernández E, Checa MR, Jara-Albarrán A: Response of ACTH to octreotide in a probable corticotropic adenoma associated with Addison's disease. Neuro Endocrinol Lett; 2007 Oct;28(5):549-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of ACTH to octreotide in a probable corticotropic adenoma associated with Addison's disease.
  • She presented an empty sella turcica and, at the age of 47, was discovered to have autonomous hypersecretion of adrenocorticotropic hormone (ACTH), suggesting a corticotropic adenoma secondary to Addison's disease, with a lack of response to high levels of dexamethasone.
  • It has been observed that SSTR5 appear more frequently than SSTR2 in corticotropic adenomas and corticosteroids downregulate octreotide sensitivity.
  • CONCLUSIONS: Octreotide did not suppress secretion of ACTH in suspected corticotropic adenoma.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / drug therapy. Adenoma / drug therapy. Adrenocorticotropic Hormone / drug effects. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Addison's Disease.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17984930.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 9002-60-2 / Adrenocorticotropic Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


71. Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici RM: The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf); 2005 Feb;62(2):210-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
  • CONCLUSION: Conventional RT is effective in the long-term control of GH-secreting pituitary adenomas, although with a high prevalence of progressive hypopituitarism.
  • [MeSH-major] Acromegaly / radiotherapy. Adenoma / radiotherapy. Adenoma / secretion. Growth Hormone / secretion. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670198.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone
  •  go-up   go-down


72. von Puttkamer J, Karges B, Wudy S, Wabitsch M: McCune-Albright syndrome with male premature pubarche of unusual origin. Horm Res; 2008;69(5):312-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apart from fibrous dysplasia of the forehead and a growth hormone- and prolactin-producing pituitary adenoma, the boy presented with premature pubarche at the age of 6 years and 11 months.
  • This increased production might be due to an activating mutation of a hormone receptor in the zona reticularis of his adrenal glands leading to an increase in sulfotransferase activity and excessive DHEAS production.
  • [MeSH-major] Fibrous Dysplasia, Polyostotic / complications. Fibrous Dysplasia, Polyostotic / diagnosis. Puberty, Precocious / etiology
  • [MeSH-minor] Adenoma / complications. Adolescent. Follow-Up Studies. Humans. Male. Pituitary Neoplasms / complications

  • Genetic Alliance. consumer health - McCune Albright syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel
  • (PMID = 18259112.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


73. Hisano M, Sakata M, Watanabe N, Kitagawa M, Murashima A, Yamaguchi K: An acromegalic woman first diagnosed in pregnancy. Arch Gynecol Obstet; 2006 Jun;274(3):171-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Elevated growth hormone (GH) levels in the serum, an inadequate suppression of GH secretion with glucose administration and a mass image in the pituitary fossa confirmed the diagnosis of acromegaly.
  • At 3 weeks after delivery, she underwent a transsphenoidal resection of a pituitary adenoma.
  • CONCLUSION: Pregnancy may lead to pituitary tumor growth and increase the risk of developing loss of vision.
  • It is important to take pituitary tumors into consideration when encountering gravida with visual disturbance.
  • [MeSH-major] Acromegaly / diagnosis. Adenoma / diagnosis. Optic Nerve Neoplasms / diagnosis. Pituitary Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374603.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dopamine Agonists; 3A64E3G5ZO / Bromocriptine
  •  go-up   go-down


74. Frank G, Pasquini E, Farneti G, Mazzatenta D, Sciarretta V, Grasso V, Faustini Fustini M: The endoscopic versus the traditional approach in pituitary surgery. Neuroendocrinology; 2006;83(3-4):240-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The endoscopic versus the traditional approach in pituitary surgery.
  • The transsphenoidal route is the most widely used technique for pituitary adenoma surgery due to its rapidity, good tolerance, effectiveness and low complication rate.
  • We reviewed the medical records of 418 patients affected by pituitary adenomas who underwent endoscopic transsphenoidal surgery between May 1998 and December 2004, and in this paper, we present the results of 381 patients who fulfilled the follow-up criteria after a minimum period of 15 months.
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Microsurgery / methods. Neurosurgical Procedures. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047389.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 9002-71-5 / Thyrotropin
  •  go-up   go-down


75. Wass J: Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues. Eur J Endocrinol; 2005 May;152(5):693-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues.

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur J Endocrinol. 2005 Jan;152(1):61-6 [15762188.001]
  • (PMID = 15879353.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  • [Number-of-references] 11
  •  go-up   go-down


76. Leach P, Abou-Zeid AH, Kearney T, Davis J, Trainer PJ, Gnanalingham KK: Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve. Neurosurgery; 2010 Nov;67(5):1205-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve.
  • BACKGROUND: The use of the fiberoptic endoscope is a recent innovation in pituitary surgery.
  • METHODS: The first 125 patients who underwent endoscopic transnasal transsphenoidal surgery for pituitary fossa lesions between 2005 and 2007 performed by 1 surgeon were studied.
  • RESULTS: There were 67 patients (54%) with nonfunctioning adenomas, 22 (18%) with acromegaly, and 10 (8%) with Cushing's disease.
  • Between study periods 1 and 2, there was a decrease in the mean duration of surgery for nonfunctioning adenomas (from 120 minutes to 91 minutes; P < .01).
  • This learning effect was not apparent for functioning adenomas, the surgery for which also took longer to perform.
  • This further highlights the benefits of subspecialization in pituitary surgery.
  • [MeSH-major] Endoscopy / statistics & numerical data. Neurosurgical Procedures / statistics & numerical data. Pituitary Neoplasms / epidemiology. Pituitary Neoplasms / surgery. Professional Competence / statistics & numerical data. Sphenoid Sinus / surgery. Workload / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871457.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Ludecke DK, Abe T: Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology; 2006;83(3-4):230-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current reports on surgical remissions, according to the strict criteria with international consensus using age- and sex-related normal levels for insulin-like growth factor-I and suppression of growth hormone (GH) with oral glucose tolerance below 1 mug/l, are more or less agreeable with values between 34 and 74%.
  • Special instruments introduced by us to visualize and remove partially invasive adenoma parts are described.
  • With intraoperative measurement of GH, small adenoma rests <3 mm can be diagnosed.
  • In grossly invasive grade 4 adenomas, which are frequent in our unit, only an 80-95% reduction in tumor mass is feasible.
  • Preoperative treatment with somatostatin analogues as used in most of our patients reduces the comorbidity and facilitates adenoma removal which is still controversially discussed in the literature.
  • [MeSH-major] Acromegaly / surgery. Adenoma / surgery. Microsurgery / methods. Neurosurgical Procedures. Pituitary Neoplasms / surgery

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047388.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  • [Number-of-references] 36
  •  go-up   go-down


78. Nishimura M, Kurimoto T, Yamagata Y, Ikemoto H, Arita N, Mimura O: Giant pituitary adenoma manifesting as homonymous hemianopia. Jpn J Ophthalmol; 2007 Mar-Apr;51(2):151-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant pituitary adenoma manifesting as homonymous hemianopia.
  • [MeSH-major] Adenoma / complications. Hemianopsia / etiology. Pituitary Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 2000 May;107(5):991-7 [10811095.001]
  • [Cites] Surv Ophthalmol. 2005 Nov-Dec;50(6):588-97 [16263371.001]
  • (PMID = 17401630.001).
  • [ISSN] 0021-5155
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Japan
  •  go-up   go-down


79. Frisén L, Jensen C: How robust is the optic chiasm? Perimetric and neuro-imaging correlations. Acta Neurol Scand; 2008 Mar;117(3):198-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Results of magnetic resonance tomography and two forms of quantitative, computerized perimetry were contrasted in 31 patients with pituitary adenomata impinging on the chiasm, prior to treatment.
  • [MeSH-major] Magnetic Resonance Imaging. Optic Chiasm / pathology. Optic Nerve Neoplasms / pathology. Pituitary Neoplasms / pathology. Visual Field Tests / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868042.001).
  • [ISSN] 1600-0404
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


80. Barzaghi LR, Losa M, Giovanelli M, Mortini P: Complications of transsphenoidal surgery in patients with pituitary adenoma: experience at a single centre. Acta Neurochir (Wien); 2007;149(9):877-85; discussion 885-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complications of transsphenoidal surgery in patients with pituitary adenoma: experience at a single centre.
  • OBJECTIVE: This paper reports the complications of transsphenoidal surgery for pituitary adenomas in a series of 1240 consecutive patients operated at our Institute between 1990 and 2004 (first operations) and indicate the clinical characteristics of patients which affected surgical morbidity and mortality.
  • METHODS: According to tumour type, there were 420 (33.9%) non-functioning pituitary adenomas (NFPA), 349 (28.1%) GH-secreting, 288 (23.2%) ACTH-secreting, 155 (12.5%) prolactin (PRL)-secreting, and 28 (2.3%) TSH-secreting adenomas.
  • There were 370 (29.8%) microadenomas and 870 (70.2%) macroadenomas of which 54 (4.4%) were giant adenomas.
  • Medical complications were significantly more frequent in patients older than 65 yr (4.9 vs. 1.4%; p = 0.009) and in patients with giant adenomas (5.6 vs. 1.6%; p = 0.03).
  • The surgical morbidity was increased in giant adenomas (15 vs. 3%; p = 0.0001), in NFPA (6.2 vs. 2.1% in secreting adenomas; p = 0.0002) and in patients older than 65 yr (6.6 vs. 3.1%; p = 0.05).
  • CONCLUSIONS: In our experience, the size of the adenoma was a risk factor for medical and surgery related complications and age over 65 yr for medical complications alone.
  • [MeSH-major] Adenoma / surgery. Neurosurgical Procedures / adverse effects. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Sphenoid Bone / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Cerebrospinal Fluid Rhinorrhea / etiology. Cranial Nerve Diseases / etiology. Epilepsy / etiology. Female. Hematoma / etiology. Humans. Intracranial Thrombosis / etiology. Male. Sella Turcica / blood supply. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17616842.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


81. Arnold JR, Arnold DF, Marland A, Karavitaki N, Wass JA: GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin Endocrinol (Oxf); 2009 Mar;70(3):435-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence.
  • BACKGROUND: Subjects with non-functioning pituitary adenomas (NFAs) frequently develop GH deficiency due to tumour expansion or as a consequence of tumour therapy.
  • RESULTS: One hundred and thirty patients were included in the study, and were followed up for a mean period of 6.8 +/- 4.2 years (median 5.7, range 1.2-17.6).
  • Twenty-three patients received GHR [16 male, 7 female, mean age at tumour diagnosis 53.7 +/- 14.6 years (range 20-80)].
  • One hundred and seven subjects did not receive GH therapy [61 male, 46 female, mean age at tumour diagnosis 56.2 +/- 14.0 years (range 20-87)].
  • The Cox regression analysis showed that after adjusting for sex, age at tumour diagnosis, cavernous sinus invasion at diagnosis and type of tumour removal (partial or complete based on postoperative scan), GH treatment was not a significant independent predictor of recurrence (P = 0.09; hazard ratio = 0.51; 95% CI, 0.24-1.12).
  • [MeSH-major] Adenoma / surgery. Growth Hormone / adverse effects. Growth Hormone / therapeutic use. Neoplasm Recurrence, Local / epidemiology. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236640.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


82. Petruson K, Stalfors J, Jacobsson KE, Ny L, Petruson B: Nitric oxide production in the sphenoidal sinus by the inducible and constitutive isozymes of nitric oxide synthase. Rhinology; 2005 Mar;43(1):18-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Ten patients, undergoing surgery for pituitary adenoma, were examined for the presence of NO gas in the sphenoidal and maxillary sinus.

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844497.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Isoenzymes; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase
  •  go-up   go-down


83. Boschetti M, Gatto F, Arvigo M, Esposito D, Rebora A, Talco M, Albertelli M, Nazzari E, Goglia U, Minuto F, Ferone D: Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells. Neuroendocrinology; 2010;92 Suppl 1:17-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells.
  • The recent depiction of dopamine receptors (DRs) in tumors that cause Cushing's syndrome (CS) has renewed the debate about the dopamine control on pituitary-adrenal axis, and opened interesting new perspectives for medical treatment of CS.
  • Corticotropic adenomas express DR subtype 2 (D(2)R), together with different SSTR subtypes (ssts), in particular sst(5).
  • [MeSH-major] Adrenal Cortex / metabolism. Corticotrophs / metabolism. Cushing Syndrome / metabolism. Pituitary Gland / metabolism. Receptors, Dopamine / metabolism
  • [MeSH-minor] Adrenal Cortex Neoplasms / metabolism. Humans. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20829613.001).
  • [ISSN] 1423-0194
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Receptors, Dopamine
  •  go-up   go-down


84. Delman BN, Fatterpekar GM, Law M, Naidich TP: Neuroimaging for the pediatric endocrinologist. Pediatr Endocrinol Rev; 2008 Feb;5 Suppl 2:708-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging of the sella and surrounding structures has become essential in the evaluation of pituitary dysfunction and its causes.
  • This article begins with a review of the normal anatomy of the sella and the imaging patterns in and about the normal pituitary gland.
  • There exists considerable variability in the size and configuration of the normal gland in all age groups, and absolute determination of a 'large' or 'small' gland can prove difficult and problematic.
  • Microadenomas are well-resolved by magnetic resonance imaging as areas with reduced or delayed enhancement relative to the normal gland.
  • Among hormonally active tumors, adrenocorticotropic hormone-releasing adenomas are most common in the first 11 years of life, while prolactinomas become more common into the teenage years.
  • Cystic lesions such as Rathke's cleft cysts are commonly seen in the gland, even in healthy children, and their presence need not correlate with any functional abnormality; however, such cysts can cause mass effect on the remaining gland, reflect hemorrhage into adenoma, or actually comprise the central portion of a more worrisome tumor such as craniopharyngioma.
  • Among inflammatory conditions, granulomatous diseases such as sarcoidosis have predilection for involvement of the suprasellar regions and can spread along perivascular spaces deep within the parenchyma.
  • Because of the association of pituitary endocrinopathies with midline anomalies, one should pay careful attention to midline structures included on a sellar survey.
  • [MeSH-major] Diagnostic Imaging. Endocrinology. Pediatrics. Pituitary Diseases / pathology. Pituitary Gland / pathology
  • [MeSH-minor] Adenoma / pathology. Cysts / pathology. Humans. Hypopituitarism / pathology. Inflammation / pathology. Magnetic Resonance Imaging. Pituitary Neoplasms / pathology


85. Gillam MP, Molitch ME, Lombardi G, Colao A: Advances in the treatment of prolactinomas. Endocr Rev; 2006 Aug;27(5):485-534
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prolactinomas account for approximately 40% of all pituitary adenomas and are an important cause of hypogonadism and infertility.
  • [MeSH-major] Pituitary Neoplasms / therapy. Prolactinoma / therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16705142.001).
  • [ISSN] 0163-769X
  • [Journal-full-title] Endocrine reviews
  • [ISO-abbreviation] Endocr. Rev.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK066044
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Hormonal; 0 / Dopamine Agonists
  • [Number-of-references] 626
  •  go-up   go-down


86. Shahlaie K, McLaughlin N, Kassam AB, Kelly DF: The role of outcomes data for assessing the expertise of a pituitary surgeon. Curr Opin Endocrinol Diabetes Obes; 2010 Aug;17(4):369-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of outcomes data for assessing the expertise of a pituitary surgeon.
  • PURPOSE OF REVIEW: Over the past four decades, advances in surgical technique, instrumentation, and anatomical knowledge have fueled the evolution and sophistication of transsphenoidal pituitary surgery.
  • Paralleling these advances have been major improvements in endocrinological and overall clinical outcomes in patients with pituitary adenomas and other parasellar lesions such as Rathke's cleft cysts and craniopharyngiomas.
  • In this review, we assess the impact of neurosurgeon expertise as a determinant of outcome in pituitary surgery.
  • RECENT FINDINGS: Published data since the 1980s indicate that remission rates, overall clinical outcomes and surgical complication rates in pituitary and parasellar surgery are related to neurosurgeon practice volume and cumulative clinical experience.
  • More recently, pituitary surgery has been increasingly performed using an endonasal endoscopic approach.
  • Reports over the last decade suggest when an experienced pituitary neurosurgeon performs a fully endoscopic or endoscope-assisted tumor removal; outcomes are similar if not better than when performed by a traditional microscopic transsphenoidal approach.
  • SUMMARY: A focused clinical practice and large transsphenoidal surgical volume appear to be important outcome determinants for patients with pituitary and parasellar tumors.
  • Strategies that may further improve patient outcomes include establishing guidelines for pituitary tumor centers of excellence and more focused residency and fellowship training in endonasal endoscopic transsphenoidal surgery.
  • Encouraging regionalization of care to higher volume pituitary tumor centers of excellence and promoting patient education on the importance of surgical expertise may further enhance pituitary patient outcomes.
  • [MeSH-major] Employee Performance Appraisal / methods. Endocrine Surgical Procedures. Pituitary Gland / surgery. Professional Competence. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20453648.001).
  • [ISSN] 1752-2978
  • [Journal-full-title] Current opinion in endocrinology, diabetes, and obesity
  • [ISO-abbreviation] Curr Opin Endocrinol Diabetes Obes
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 99
  •  go-up   go-down


87. Suzuki M, Egashira N, Kajiya H, Minematsu T, Takekoshi S, Tahara S, Sanno N, Teramoto A, Osamura RY: ACTH and alpha-subunit are co-expressed in rare human pituitary corticotroph cell adenomas proposed to originate from ACTH-committed early pituitary progenitor cells. Endocr Pathol; 2008;19(1):17-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACTH and alpha-subunit are co-expressed in rare human pituitary corticotroph cell adenomas proposed to originate from ACTH-committed early pituitary progenitor cells.
  • The functional differentiation of pituitary cells and adenomas follows the combination of transcription factors and co-factors in three cell lineages [growth hormone-prolactin-thyroid-stimulating hormone lineage, adrenocorticotrophic hormone (ACTH)/pro-opiomelanocortin (POMC) lineage, and follicular stimulating hormone (FSH)/luteinizing hormone (LH) lineage], which include Pit-1, GATA-2, SF-1, NeuroD1/beta2, Tpit, ERalpha, and others.
  • Only rarely are hormones from different lineages co-expressed in the same adenoma cells.
  • Most corticotroph cell adenomas belonging to the ACTH/POMC lineage are mono-hormonal.
  • In our study of 89 corticotroph cell adenomas, 5 cases expressed both ACTH and alpha-subunit; these adenomas did not express any other anterior pituitary hormones or subunits.
  • To clarify the mechanism involved, we studied the transcription factors that regulate pituitary cell differentiation.
  • As ACTH and alpha-subunit are the earliest hormones to appear during development, we speculate that these particular adenomas are derived from committed ACTH progenitor cells.
  • The molecular process governing functional differentiation of these adenomas requires further investigation.
  • [MeSH-major] Adenoma / genetics. Adrenocorticotropic Hormone / genetics. Gene Expression Regulation, Neoplastic. Glycoprotein Hormones, alpha Subunit / genetics. Pituitary Neoplasms / genetics. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 1998 May;48(5):647-54 [9666878.001]
  • [Cites] Mol Cell Biol. 1987 Nov;7(11):3994-4002 [2828923.001]
  • [Cites] Endocr Pathol. 2006 Spring;17(1):35-43 [16760578.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2165-70 [8964846.001]
  • [Cites] Mol Endocrinol. 2006 Nov;20(11):2898-908 [16840533.001]
  • [Cites] Genes Dev. 2003 Mar 15;17(6):738-47 [12651892.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):11-7 [11796836.001]
  • [Cites] Mol Endocrinol. 2004 Apr;18(4):995-1003 [14726486.001]
  • [Cites] Neuroendocrinology. 1986;43(3):308-16 [3016583.001]
  • [Cites] Neurosurgery. 1990 Mar;26(3):397-403 [1690866.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):789-94 [10923914.001]
  • [Cites] Acta Pathol Jpn. 1977 Jul;27(4):495-509 [199043.001]
  • [Cites] Pituitary. 1999 May;1(3-4):269-71 [11081207.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1102-5 [12379758.001]
  • [Cites] Acta Neuropathol. 2001 Oct;102(4):398-403 [11603817.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Dec;80(12):3621-7 [8530610.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):264-9 [11037346.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):892-9 [11557786.001]
  • [Cites] Mol Endocrinol. 1994 Jul;8(7):878-85 [7527122.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jan;81(1):80-3 [8550798.001]
  • [Cites] J Endocrinol. 2002 Mar;172(3):477-87 [11874696.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2476-83 [11397843.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1220-5 [10720066.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Nov;77(5):1275-80 [8077321.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):245-51 [10623673.001]
  • [Cites] J Endocrinol Invest. 2003 Oct;26(10):957-65 [14759067.001]
  • [Cites] Tumori. 2000 May-Jun;86(3):229-32 [10939604.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Sep;43(3):383-6 [7586610.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1987;411(4):323-30 [2442884.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(4):361-7 [2173251.001]
  • [Cites] J Clin Pathol. 1999 Feb;52(2):107-11 [10396237.001]
  • [Cites] Acta Neuropathol. 1996;91(3):263-8 [8834538.001]
  • [Cites] Dev Biol. 2004 Jan 15;265(2):329-40 [14732396.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jun;78(6):1497-504 [7515390.001]
  • [Cites] Eur J Endocrinol. 1995 Jul;133(1):25-32 [7542980.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;413(1):61-8 [2453972.001]
  • (PMID = 18228160.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Glycoprotein Hormones, alpha Subunit; 0 / NEUROD1 protein, human; 0 / Transcription Factor Pit-1; 0 / Transcription Factors; 66796-54-1 / Pro-Opiomelanocortin; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


88. Botelho CH, Magalhães AV, Mello PA, Schmitt FC, Casulari LA: Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr; 2006 Mar;64(1):60-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas.
  • The subcellular events implicated on the formation and behavior of pituitary adenomas are not fully understood.
  • In this study we investigated the presence of p53, Ki-67 and c-erb B2 in 38 pituitary adenomas with immunohistochemical positivity for GH and prolactin (n=26; 68.4%), for prolactin (n=9; 23.7%) and for GH (n=3. 7.8%).
  • [MeSH-major] Growth Hormone / secretion. Ki-67 Antigen / analysis. Neoplasm Proteins / analysis. Pituitary Neoplasms / metabolism. Prolactinoma / metabolism. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622555.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; 9002-72-6 / Growth Hormone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


89. Hussaini IM, Trotter C, Zhao Y, Abdel-Fattah R, Amos S, Xiao A, Agi CU, Redpath GT, Fang Z, Leung GK, Lopes MB, Laws ER Jr: Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line. Am J Pathol; 2007 Jan;170(1):356-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line.
  • The complete resection of pituitary adenomas (PAs) is unlikely when there is an extensive local dural invasion and given that the molecular mechanisms remain primarily unknown.
  • Gene clustering revealed a robust eightfold increase in matrix metalloproteinase (MMP)-9 expression in surgically resected human invasive PAs and in the (nonfunctioning) HP75 human pituitary tumor-derived cell line treated with phorbol-12-myristate-13-acetate; these results were confirmed by real-time polymerase chain reaction, gelatin zymography, reverse transcriptase-polymerase chain reaction, Western blot, immunohistochemistry, and Northern blot analyses.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2005;82(3-4):208-14 [16601360.001]
  • [Cites] Endocrinology. 1994 Jul;135(1):416-22 [8013379.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):22348-54 [10806212.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2931-5 [10946906.001]
  • [Cites] Neurosci Lett. 2000 Sep 1;290(3):201-4 [10963898.001]
  • [Cites] Neurosurgery. 2001 Oct;49(4):857-62; discussion 862-3 [11564246.001]
  • [Cites] Exp Cell Res. 2001 Dec 10;271(2):344-55 [11716547.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):195-208 [11838791.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1262-7 [11889197.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):137-43 [12469196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1034-9 [12552124.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15056-64 [12586837.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2251-5 [12727847.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):18140-5 [12642591.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 30;305(2):428-33 [12745093.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4218-24 [12874029.001]
  • [Cites] Glia. 2003 Sep;43(3):254-64 [12898704.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):471-8 [12904990.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):269-85 [14619979.001]
  • [Cites] J Pathol. 2006 May;209(1):15-24 [16463268.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5119-26 [14602737.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22118-23 [15037605.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5693-701 [15313909.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Nov;77(5):1125-9 [8077302.001]
  • [Cites] FASEB J. 1995 Apr;9(7):484-96 [7737456.001]
  • [Cites] Cell Signal. 1995 Nov;7(8):793-801 [8593248.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Feb;81(2):656-62 [8636285.001]
  • [Cites] J Neurosurg. 1996 Aug;85(2):329-34 [8755764.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(4):390-5 [8738388.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] J Endocrinol. 1997 Apr;153(1):131-7 [9135578.001]
  • [Cites] Horm Res. 1997;47(4-6):227-34 [9167956.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2209-15 [9187123.001]
  • [Cites] J Endocrinol. 1998 Sep;158(3):425-33 [9846172.001]
  • [Cites] Mol Pharm. 2004 Jan 12;1(1):9-22 [15832497.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):143-51 [15994756.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8366-71 [16166314.001]
  • [Cites] J Med Invest. 2005 Aug;52(3-4):151-8 [16167532.001]
  • [Cites] J Clin Neurosci. 2005 Sep;12(7):791-4 [16198918.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10214-22 [16288009.001]
  • [Cites] Int J Cancer. 1982 Nov 15;30(5):669-73 [6295970.001]
  • [Cites] J Neurosurg. 1986 Mar;64(3):402-7 [3950720.001]
  • [Cites] Biochim Biophys Acta. 1987 Nov 25;907(3):191-217 [2823896.001]
  • [Cites] Endocrinology. 1990 May;126(5):2567-76 [2109689.001]
  • [Cites] Int J Cancer. 1992 Mar 12;50(5):724-30 [1347514.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):14543-6 [1378833.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7427-31 [1502154.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):635-42 [8097303.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1432-40; discussion 1440-1 [10598711.001]
  • (PMID = 17200207.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS035122; United States / NCI NIH HHS / CA / R01 CA090851; United States / NINDS NIH HHS / NS / R29 NS035122; United States / NINDS NIH HHS / NS / NS35122; United States / NCI NIH HHS / CA / CA90851
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Pyrones; 0 / RNA, Small Interfering; 56937-68-9 / phorbolol myristate acetate; EC 2.7.11.13 / Protein Kinase C; EC 3.4.24.35 / Matrix Metalloproteinase 9; NI40JAQ945 / Tetradecanoylphorbol Acetate; SSJ18CG55E / hispidin
  • [Other-IDs] NLM/ PMC1762693
  •  go-up   go-down


90. Rozen TD: Resolution of SUNCT after removal of a pituitary adenoma in mild acromegaly. Neurology; 2006 Aug 22;67(4):724
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resolution of SUNCT after removal of a pituitary adenoma in mild acromegaly.
  • [MeSH-major] Acromegaly / complications. Adenoma / complications. Adenoma / surgery. Pituitary Neoplasms / complications. Pituitary Neoplasms / surgery. SUNCT Syndrome / etiology. SUNCT Syndrome / prevention & control

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16924039.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P: Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf); 2007 Aug;67(2):282-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
  • OBJECTIVE: To evaluate the antihormonal and antitumour efficacy of long-term (up to 18 years) primary treatment with SSTa in patients with GH-secreting pituitary adenoma responsive to SSTa.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Growth Hormone / blood. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Insulin-Like Growth Factor I / analysis. Pituitary Neoplasms / drug therapy. Somatostatin / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2005 Oct;90(10):5627-31 [16046586.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4483-8 [15899958.001]
  • [Cites] Trends Endocrinol Metab. 2005 Nov;16(9):407-13 [16213744.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):85-92 [16263832.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Feb;64(2):209-14 [16430722.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1397-403 [16449332.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3779-85 [11061538.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Nov;85(11):4099-103 [11095439.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4596-602 [11134114.001]
  • [Cites] Lancet. 2001 Feb 10;357(9254):425-31 [11273062.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2779-86 [11397887.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4072-7 [11549628.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):99-104 [11788630.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):65-71 [11849248.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4054-8 [12213843.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4142-6 [12213862.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63 [12364434.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3090-8 [12843148.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3105-12 [12843150.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4709-19 [14557445.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5258-65 [14602759.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5414-21 [14602782.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):667-74 [14764779.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):102-52 [14769829.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S101-6 [15135788.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):209-15 [15272916.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jul;79(1):113-8 [8027215.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Apr;18(4):765-72 [9127047.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Mar;48(3):311-6 [9578821.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1962 Jun;87:989-1008 [13885978.001]
  • [Cites] Eur J Endocrinol. 2005 Mar;152(3):379-87 [15757854.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1856-63 [15613435.001]
  • [Cites] Eur J Endocrinol. 2005 Jan;152(1):61-6 [15762188.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):569-74 [15817912.001]
  • [Cites] Lancet. 2005 May 7-13;365(9471):1644-6 [15885297.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):135-41 [15994755.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10 [15827109.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4465-73 [15886238.001]
  • (PMID = 17524029.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Dopamine Agonists; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC1974833
  •  go-up   go-down


92. Kristof RA, Kirchhofer D, Handzel D, Neuloh G, Schramm J, Mueller CA, Eter N: Functional impairments caused by chiasma syndromes prior to and following transsphenoidal pituitary adenoma surgery. Acta Neurochir (Wien); 2010 Aug;152(8):1283-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional impairments caused by chiasma syndromes prior to and following transsphenoidal pituitary adenoma surgery.
  • PURPOSE: To describe the functional impairment caused by chiasma syndromes (CS) prior to and following transsphenoidal pituitary adenoma surgery.
  • METHODS: Pertinent data of a successive series of patients operated transsphenoidally for the first time for pituitary adenoma were retrospectively analyzed.
  • [MeSH-major] Adenoma / surgery. Hypophysectomy / adverse effects. Optic Chiasm / injuries. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20454981.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


93. Mouton F, Faivre-Defrance F, Cortet-Rudelli C, Assaker R, Soto-Ares G, Defoort-Dhellemmes S, Blond S, Wemeau JL, Vantyghem MC: TSH-secreting adenoma improved with cabergoline. Ann Endocrinol (Paris); 2008 Jun;69(3):244-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TSH-secreting adenoma improved with cabergoline.
  • TSH-secreting adenomas are rare tumors, representing only 0.5 to 2.5% of pituitary adenomas.
  • Magnetic resonance (MR) imaging shows a pituitary tumor, the main differential diagnosis being resistance to thyroid hormones.
  • We suggest that cabergoline should be considered as an alternative treatment in cases of pituitary adenomas that resist traditional treatments.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ergolines / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / secretion. Thyrotropin / secretion

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486933.001).
  • [ISSN] 0003-4266
  • [Journal-full-title] Annales d'endocrinologie
  • [ISO-abbreviation] Ann. Endocrinol. (Paris)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ergolines; 06LU7C9H1V / Triiodothyronine; 9002-71-5 / Thyrotropin; LL60K9J05T / cabergoline; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


94. Lindholm J: A century of pituitary surgery: Schloffer's legacy. Neurosurgery; 2007 Oct;61(4):865-7; discussion 867-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A century of pituitary surgery: Schloffer's legacy.
  • Although pituitary tumors were well recognized by the end of the 20th century, very few surgeons had attempted to remove such tumors.
  • In 1906, Hermann Schloffer at the Innsbruck University Clinic of Surgery reviewed the subject of pituitary surgery.
  • Very little was known about the function of the pituitary, and no reports had yet been published on attempts to surgically remove pituitary neoplasms.
  • On March 16, 1907, Schloffer performed the first transsphenoidal operation for a pituitary adenoma.
  • [MeSH-major] Adenoma / history. Neurosurgery / history. Pituitary Neoplasms / history

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986949.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article; Portraits
  • [Publication-country] United States
  • [Personal-name-as-subject] Schloffer H
  •  go-up   go-down


95. Tamasauskas A, Sinkūnas K, Draf W, Deltuva V, Matukevicius A, Rastenyte D, Vaitkus S: Management of cerebrospinal fluid leak after surgical removal of pituitary adenomas. Medicina (Kaunas); 2008;44(4):302-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of cerebrospinal fluid leak after surgical removal of pituitary adenomas.
  • METHODS: During the period from 1995 to 2005, 313 patients underwent 356 transsphenoidal operations for pituitary adenoma.
  • RESULTS: Adenoma was totally removed in 198 (55.6%) cases out of 356.
  • [MeSH-major] Adenoma / surgery. Cerebrospinal Fluid Rhinorrhea / surgery. Pituitary Neoplasms / surgery. Postoperative Complications / surgery. Prolactinoma / surgery. Sella Turcica / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / surgery. Aged. Bone Transplantation. Cellulose, Oxidized / therapeutic use. Drug Combinations. Female. Fibrinogen / therapeutic use. Follow-Up Studies. Humans. Intraoperative Complications. Male. Middle Aged. Surgical Sponges. Thrombin / therapeutic use. Time Factors

  • Genetic Alliance. consumer health - Cerebrospinal Fluid Leak.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469507.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Cellulose, Oxidized; 0 / Drug Combinations; 0 / TachoSil; 82347-53-3 / Surgicel; 9001-32-5 / Fibrinogen; EC 3.4.21.5 / Thrombin
  •  go-up   go-down


96. Chang CV, Felicio AC, Toscanini AC, Teixeira MJ, Cunha-Neto MB: Pituitary tumor apoplexy. Arq Neuropsiquiatr; 2009 Jun;67(2A):328-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary tumor apoplexy.
  • Pituitary tumor apoplexy is a medical emergency due to acute infarction or hemorrhage in the pituitary gland.
  • In this review, the authors discuss the sellar anatomy, the pituitary gland and adenomas' vascularization and the general aspects of the syndrome such as its ethiopatogenesis, predisposing factors, clinical features, treatment and prognosis.
  • [MeSH-major] Pituitary Apoplexy / etiology. Pituitary Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19547836.001).
  • [ISSN] 1678-4227
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 50
  •  go-up   go-down


97. Sy J, Ang LC: Cytomorphologic spectrum of mixed pituitary adenoma-gangliocytomas: a report of two cases. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):981-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic spectrum of mixed pituitary adenoma-gangliocytomas: a report of two cases.
  • BACKGROUND: Mixed pituitary adenoma-gangliocytomas are rare tumors with a broad morphologic spectrum.
  • CONCLUSION: The diagnostic features of mixed pituitary adenoma-gangliocytomas can be recognized on intraoperative smear preparations.
  • Careful search for a neuronal component should be made, especially if there is a clinical history of a pituitary adenoma showing incomplete response to hormonal therapy.
  • [MeSH-major] Ganglioneuroma / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053582.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Levy MJ, Classey JD, Maneesri S, Meeran K, Powell M, Goadsby PJ: The relationship between neuropeptide Y expression and headache in pituitary tumours. Eur J Neurol; 2006 Feb;13(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between neuropeptide Y expression and headache in pituitary tumours.
  • Patients with pituitary tumours often present with disabling headache but there is no clear relationship between tumour size and headache.
  • Neuropeptide Y (NPY) has been identified in pituitary tumours and may serve as a biochemical marker of the propensity for headache.
  • Using immunohistochemical techniques we examined 27 consecutive pituitary adenoma specimens for NPY (including one normal postmortem control anterior pituitary specimen).
  • NPY positive immunoreactivity was seen in 13 tumour specimens (50%, 13 of 26 pituitary tumour specimens), characterized by cytoplasmic and nuclear staining patterns.
  • We did not observe NPY in the normal anterior pituitary control specimen.
  • NPY was present in four of five (80%) growth hormone-secreting tumours and two of two (100%) prolactinomas, compared with four of 11 (36%) non-functioning adenomas.
  • The mechanism of many pituitary tumour-associated headaches remains undetermined.
  • The significance of NPY positivity in pituitary tumours is unknown, although the results of this study may implicate this peptide in the control of somatotroph and lactotroph activity.
  • Our data do not support a clear role for NPY pituitary tumour-associated headache.
  • [MeSH-major] Headache / etiology. Headache / metabolism. Neuropeptide Y / metabolism. Pituitary Neoplasms / complications. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Headache.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16490041.001).
  • [ISSN] 1351-5101
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neuropeptide Y
  •  go-up   go-down


99. Fedele M, Fusco A: Role of the high mobility group A proteins in the regulation of pituitary cell cycle. J Mol Endocrinol; 2010 Jun;44(6):309-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the high mobility group A proteins in the regulation of pituitary cell cycle.
  • Pituitary cells are particularly sensitive to alterations of the cell cycle machinery.
  • In fact, mutations affecting expression of proteins critical for cell cycle progression, including retinoblastoma protein, cyclins D1 and D3, p16(INK4A), and p27(kip1), are frequent in human pituitary adenomas.
  • Similarly, both targeted disruption and overexpression of either cell cycle inhibitors or activators, respectively, lead to the development of pituitary adenomas in mice.
  • Recent evidence has added the high mobility group A (HMGA) proteins as a new class of cell cycle regulators that play significant roles in the pathways that lead to pituitary tumor evolution in both humans and experimental animal models.
  • Here, we first review the role of the cell cycle in pituitary tumorigenesis, as witnessed by human pathology and transgenic mice; and then, we focus on HMGA proteins and their cell cycle-related role in pituitary tumorigenesis.
  • [MeSH-major] Cell Cycle / physiology. HMGA Proteins / metabolism. Pituitary Gland / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Animals. Cell Cycle Proteins / genetics. Cyclin D1 / genetics. Cyclin D3 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Female. Humans. Male. Mice. Mice, Transgenic / genetics. Pituitary Neoplasms / genetics. Retinoblastoma Protein / genetics. Tumor Suppressor Proteins / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219853.001).
  • [ISSN] 1479-6813
  • [Journal-full-title] Journal of molecular endocrinology
  • [ISO-abbreviation] J. Mol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin D3; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / HMGA Proteins; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Number-of-references] 84
  •  go-up   go-down


100. Weil RJ, Vortmeyer AO, Nieman LK, Devroom HL, Wanebo J, Oldfield EH: Surgical remission of pituitary adenomas confined to the neurohypophysis in Cushing's disease. J Clin Endocrinol Metab; 2006 Jul;91(7):2656-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical remission of pituitary adenomas confined to the neurohypophysis in Cushing's disease.
  • CONTEXT: Partial or total removal of the pituitary cures 60-80% of patients with Cushing's disease (CD) in whom an adenoma cannot be identified at surgery.
  • DESIGN/PATIENTS: As part of a series of prospective studies of CD, we identified 12 patients (34.5 +/- 19.9 yr; 11 females; four children) with tumors located completely within the neurohypophysis among 730 patients undergoing surgery for CD.
  • CONCLUSION: We report a new subset of patients with CD, ACTH-secreting adenomas that arise wholly within the posterior lobe of the pituitary gland.
  • In cases of CD in which an adenoma is not identified in the adenohypophysis and in patients with persistent hypercortisolism after complete or partial excision of the anterior lobe, tumor within the neurohypophysis should be considered; selective adenomectomy of a neurohypophyseal, ACTH-secreting tumor can produce long-term remission.
  • [MeSH-major] Adenoma / surgery. Pituitary ACTH Hypersecretion / surgery. Pituitary Gland, Posterior / surgery. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636117.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down






Advertisement